 
 
Official Title: AN OPEN -LABEL, TREATMENT, INVESTIGATOR -INITIATED STUDY, 
ON THE DURATION AND EFFICACY OF AZSTARYS 
SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE) ON 
ADULT ADHD SYMPTOMS AND EXECUTIVE FUNCTION 
THROUGHOUT THE DAY INTO EARLY EVENING  
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  s22-01003  
Document Type:  Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • December 18, 2023  
 
 
Study #: s22-01003   Page 1 of 64 
  AN OPEN- LABEL,  TREATMENT,  INVESTIGATOR -INITIATED  STUDY,  ON THE  
DURATION  AND  EFFICACY  OF AZSTARYS  SERDEXMETHYLPHENIDATE  AND  
DEXMETHYLPHENIDATE) ON ADULT  ADHD SYMPTOMS  AND  EXECUTIVE  
FUNCTION  THROUGHOUT  THE  DAY INTO EARLY  EVENING  
 
 
Principal  Investigator:  Lenard  Adler,  MD 
Department of  Psychiatry  
NYU Grossman  School  of Medicine,   
One Park  Ave, New  York,  NY 10016 
Lenard.Adler@nyulangone.org  
212-263-3580  
Additional  
Investigators: Marianne  Guschwan,  MD 
Department of  Psychiatry  
NYU Grossman  School  of Medicine,   
One Park  Ave, New  York,  NY 10016 
Marianne.Guschwan@nyulangone.org  
212-263-3580 
 
Deepti  Anbarasan, MD 
Department of  Psychiatry  
NYU Grossman  School  of Medicine,   
One Park  Ave, New  York,  NY 10016 
Lenard.Adler@nyulangone.org  
212-263-3580  
NYULMC  Study  
Number:  s22-01003 
Funding  Sponsor:   Charles  Oh, MD 
Corium,  LLC  
11 Farnsworth  Street 
4th Floor  
Boston,  MA 02210  
IND Number:   N/A 
Regulatory  Sponsor:  Lenard  Adler  MD 
Study  Product:  Azstarys  (Serdexmethylphenidate  and Dexmethylphenidate ) 
Study  Product  
Provider:   Corium,  LLC 
ClinicalTrials.gov  
Number   Pending  
 
Initial  version: 08 June  2022 (Initial  concept  approved by Corium  LLC) 
Amended: 14 November  2022 (revision  accepted by Corium  LLC) 
Amended: 22 February  2022(IRB  approved 21  March  2023) 
Study #: s22-01003   Page 2 of 64 
  Amended: 10 July 2023 included  Corium  LLC revisions,  Revised  14 August  2023(IRB approved 
21 September 2023) 
Amended: 12/18/2023 Sponsor  approved  
 
Statement  of Compliance  
This study will be conducted in accordance  with  the Code  of Federal Regulations on the Protection  
of Human Subjects  (45 CFR Part 46), 21 CFR Parts  50, 56, 312, and 812 as applicable, any other  
applicable  US government  research  regulations, and institutional  research  policies  and procedures.  
The International  Conference  on Harmonization (“ICH”)  Guideline  for Good  Clinical Practice  
(“GCP”)  (sometimes  referred to as “ICH -GCP” or “E6”)  will be applied only to the extent  that it is 
compatible with  FDA and DHHS  regulations. The Principal Investigator  will assure  that no 
deviation  from,  or changes to the protocol  will take place  without  prior agreement  from  the Corium  
LLC and documented  approval from  the Institutional  Review  Board  (IRB),  except  where  necessary  
to eliminate  an immediate hazard(s) to the trial participants.  All personnel  involved  in the conduct  
of this study have  completed  Human Subjects  Protection  Training. 
  
Study #: s22-01003   Page 3 of 64 
  Table  of Contents  
 
 
STATEMENT OF COMPLIANCE  .......................................................................................... 2 
LIST OF ABBREVIATIONS  ................................................................................................... 6 
PROTOCOL  SUMMARY  ......................................................................................................... 9 
FLOW  DIAGRAM  .................................................................................................................... 12 
1. KEY ROLES  ...................................................................................................................... 13 
2. INTRODUCTION,  BACKGROUND INFORMATION AND  SCIENTIFIC  RATIONALE
 ............................................................................................................................................. 13 
2.1. BACKGROUND  INFORMATION AND  RELEVANT  LITERATURE  ................................. 13 
2.2. NAME AND  DESCRIPTION OF THE AGENT  .............................................................. 15 
2.2.1. Preclinical Data  ..................................................................................................... 15 
2.2.2. Clinical Data  to Date ............................................................................................. 15 
2.2.3. Dose  Rationale (if applicable) ................................................................................ 16 
2.3. RATIONALE  ............................................................................................................ 18 
2.4. POTENTIAL  RISKS  & BENEFITS  ............................................................................. 18 
2.4.1. Known  Potential Risks label (fda.gov) Reference ID: 4755866 ............................ 18 
2.4.2. Minimizing Risks  ................................................................................................... 18 
2.4.3. Known  Potential Benefits  ...................................................................................... 21 
3. OBJECTIVES  AND  PURPOSE  ..................................................................................... 21 
3.1. PRIMARY  OBJECTIVE  ............................................................................................. 21 
3.2. SECONDARY  OBJECTIVES  (IF APPLICABLE ) ............................................................ 21 
4. STUDY  DESIGN  AND  ENDPOINTS  ............................................................................ 22 
4.1.
 DESCRIPTION OF STUDY  DESIGN  ........................................................................... 22 
4.2. STUDY  ENDPOINTS  ................................................................................................ 22 
4.2.1. Primary Study  Endpoints  ..................................................................................... 22 
4.2.2. Secondary  Study  Endpoints  .................................................................................. 22 
4.2.3. Exploratory  Endpoints  ........................................................................................... 23 
5. STUDY  ENROLLMENT AND WITHDRAWAL .......................................................... 23 
5.1. INCLUSION CRITERIA  ............................................................................................. 23 
5.2. EXCLUSION CRITERIA  ............................................................................................ 23 
5.3. VULNERABLE SUBJECTS  ........................................................................................ 24 
5.4. STRATEGIES  FOR RECRUITMENT  AND  RETENTION  ................................................ 24 
5.5. DURATION OF STUDY  PARTICIPATION  ................................................................... 25 
5.6. TOTAL  NUMBER OF PARTICIPANTS  AND  SITES ...................................................... 25 
5.7. PARTICIPANT  WITHDRAWAL  OR TERMINATION  ..................................................... 26 
5.7.1. Reasons for Withdrawal  or Termination .............................................................. 26 
5.7.2. Handling of Participant Withdrawals or Termination  ........................................ 26 
5.8. PREMATURE TERMINATION OR SUSPENSION OF STUDY  ........................................ 27 
6. STUDY  AGENT  (STUDY  DRUG,  DEVICE, BIOLOGIC,  VACCINE  ETC.)  AND/OR  
PROCEDURAL  INTERVENTION  ................................................................................ 27 
6.1.
 STUDY  AGENT (S) AND  CONTROL  DESCRIPTION  ..................................................... 27 
6.1.1. Acquisition ............................................................................................................. 27 
6.1.2. Formulation, Appearance, Packaging, and Labeling ........................................... 28 
6.1.3. Product  Storage  and Stability ............................................................................... 28 
6.1.4. Preparation  ............................................................................................................ 28 
6.1.5. Dosing and Administration ................................................................................... 28 
6.1.6. Route of Administration ........................................................................................ 28 
Study #: s22-01003   Page 4 of 64 
  6.1.7. Starting Dose and Dose  Escalation  Schedule  ....................................................... 28 
6.1.8. Dose  Adjustments/Modifications/Delays ............................................................. 29 
6.1.9. Duration  of Therapy .............................................................................................. 29 
6.1.10. Tracking of Dose  .................................................................................................... 29 
6.2. STUDY  AGENT  ACCOUNTABILITY  PROCEDURES  .................................................... 30 
6.2.1. Procedures for Training of Clinicians on Procedural  Intervention  ..................... 30 
7. STUDY  PROCEDURES  AND  SCHEDULE  .. ERROR! BOOKMARK  NOT  DEFINED.  
7.1. STUDY  PROCEDURES /EVALUATIONS  ...................................................................... 33 
7.1.1. Study  Specific Procedures  .................................. Error! Bookmark not defined.  
7.1.2. Standard of Care Study  Procedures  ..................................................................... 35 
7.2. LABORATORY  PROCEDURES /EVALUATION  ......E RROR ! BOOKMARK NOT DEFINED . 
7.2.1. Clinical Laboratory  Evaluations ........................................................................... 35 
7.3. STUDY  SCHEDULE : ALL VISITS  WILL  ALL BE CONDUCTED  AS HYBRID ; CONDUCTED  IN CLINIC 
AND/OR REMOTE /WEBEX/REDCAP  .......................................................................... 35 
7.3.1. Screening  ................................................................................................................ 35 
7.3.2. Intermediate Visits (Post-2-week  Observation  Stabilization ................................ 36 
7.3.3. Final Study  Visit .................................................................................................... 37 
7.3.4. Withdrawal/Early Termination Visit  .................................................................. 38 
7.3.5.
 Unscheduled  Visit .................................................................................................. 38 
7.4. CONCOMITANT  MEDICATIONS , TREATMENTS , AND  PROCEDURES  ........................ 38 
7.5. JUSTIFICATION FOR SENSITIVE PROCEDURES  ERROR ! BOOKMARK NOT DEFINED . 
7.5.1. Precautionary  Medications,  Treatments, and Procedures  ................................... 39 
7.6. PROHIBITED  MEDICATIONS , TREATMENTS , AND  PROCEDURES  ............................ 39 
7.7. RESCUE MEDICATIONS , TREATMENTS , AND  PROCEDURES ERROR ! BOOKMARK  NOT 
DEFINED . 
7.8. PARTICIPANT  ACCESS  TO STUDY  AGENT  AT STUDY CLOSURE  .............................. 40 
8. ASSESSMENT OF SAFETY  ........................................................................................... 40 
8.1.1. Definition of Adverse Events (AE)  ......................................................................... 40 
8.1.2. Definition of Serious Adverse Events (SAE) ......................................................... 40 
8.1.3. Definition of Unanticipated  Problems (UP) .......................................................... 41 
8.2. CLASSIFICATION OF AN ADVERSE EVENT  .............................................................. 41 
8.2.1. Severity of Event  .................................................................................................... 41 
8.2.2. Relationship to Study  Agent  .................................................................................. 41 
8.2.3. Expectedness  ........................................................................................................... 42 
8.3. TIME PERIOD  AND  FREQUENCY  FOR EVENT  ASSESSMENT  AND  FOLLOW -UP ....... 42 
8.4.
 REPORTING  PROCEDURES  – NOTIFYING THE IRB ................................................. 43 
8.4.1. Adverse Event  Reporting ....................................................................................... 43 
8.4.2. Serious Adverse Event  Reporting  .......................................................................... 45 
8.4.3. Unanticipated  Problem  Reporting  ........................................................................ 45 
8.4.4. Reporting of  Pregnancy  .......................................................................................... 46 
8.5. REPORTING  PROCEDURES  – NOTIFYING CORIUM  LLC ......................................... 46 
8.6. DATA SAFETY MONITORING ................................................................................... 46 
8.7. STUDY  HALTING  RULES  ......................................................................................... 47 
8.8. SAFETY  OVERSIGHT  ........................................E RROR ! BOOKMARK NOT DEFINED . 
9. CLINICAL  MONITORING  ............................................................................................. 47 
10. STATISTICAL CONSIDERATIONS  ............................................................................ 47 
10.1. STATISTICAL AND  ANALYTICAL  PLANS  (SAP)  ....................................................... 47 
10.2. STATISTICAL HYPOTHESES  .............................E RROR ! BOOKMARK NOT DEFINED . 
Study #: s22-01003   Page 5 of 64 
  10.3. DESCRIPTION OF STATISTICAL  METHODS  ............................................................. 48 
10.3.1. Analysis of the Primary Efficacy Endpoint(s) ...................................................... 49 
10.3.2. Analysis of the Secondary  Endpoint(s) ................................................................. 49 
10.3.3. Safety Analyses  ...................................................................................................... 50 
10.3.4. Adherence and Retention  Analyses  ....................................................................... 50 
10.3.5. Planned Interim  Analysis ...................................................................................... 50 
10.4. SAMPLE SIZE .......................................................................................................... 50 
10.5. MEASURES  TO MINIMIZE  BIAS ........................E RROR ! BOOKMARK NOT DEFINED . 
10.5.1. Evaluation of Success  of Blinding- Not required, treatment  with open -label Azstarys
 ............................................................................. Error! Bookmark not defined.  
10.5.2. Breaking  the Study  Blind/Participant Code  ..... Error! Bookmark not defined.  
11. SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE  DATA/DOCUMENTS  ....... 51 
12. QUALITY ASSURANCE AND  QUALITY CONTROL  ............................................... 51 
13. ETHICS/PROTECTION  OF HUMAN  SUBJECTS  ..................................................... 52 
13.1. ETHICAL  STANDARD  .............................................................................................. 52 
13.2. INSTITUTIONAL  REVIEW  BOARD  ............................................................................ 53 
13.3. INFORMED  CONSENT  PROCESS  .............................................................................. 24 
13.3.1. Consent/Assent  and Other Informational Documents Provided  to Participants Error! 
Bookmark no t defined.  
13.3.2. Consent  Procedures and Documentation  ........... Error! Bookmark not defined.  
13.4. POSTING  OF CLINICAL  TRIAL  CONSENT  FORM ...................................................... 53 
13.5. PARTICIPANT  AND  DATA  CONFIDENTIALITY  .......................................................... 53 
14. DATA  HANDLING  AND RECORD  KEEPING  ........................................................... 54 
14.1. DATA COLLECTION AND  MANAGEMENT  RESPONSIBILITIES  .................................. 54 
14.2. STUDY  RECORDS  RETENTION  ................................................................................ 55 
14.3. PROTOCOL  DEVIATIONS  ......................................................................................... 56 
14.4. PUBLICATION AND  DATA  SHARING  POLICY  ........................................................... 56 
15. STUDY  FINANCES  ......................................................................................................... 57 
15.1. FUNDING  SOURCE  .................................................................................................. 57 
15.2. COSTS TO THE  PARTICIPANT  .................................................................................. 58 
15.3. PARTICIPANT  REIMBURSEMENTS  OR PAYMENTS  ................................................... 58 
16. CONFLICT  OF INTEREST  POLICY  ........................................................................... 58 
17. REFERENCES  ................................................................................................................. 59 
18. SCHEDULE  OF EVENTS  ............................................................................................... 62 
 
  
Study #: s22-01003   Page 6 of 64 
   
List of Abbreviations  
ACDS  Adult  ADHD  Clinical  Diagnostic  Scale  
AE Adverse  Event/Adverse  Experience  
AISRS  Adult  ADHD  Investigator  Symptom  Rating  Scale  
AMSES  ADHD  Medication  Smoothness  of Effect  Scale  
ASRS  Adult  ADHD  Self-Report  Scale  
BRIEF -A Behavior  Rating  Inventory  of Executive  Function - Adult  Version  
CGI-S Clinical  Global  Impression:  Severity  of Illness  
CFR  Code  of Federal  Regulations  
CM Concomitant  Medications  
CRF  Case  Report  Form  
CSOC  Clinical  Study  Oversight  Committee  
C-SSRS  Columbia  Suicide  Severity  Rating  Scale  
CT Clinical  Trial  
d/c’d Discontinued  
DCC  Data  Coordinating  Center  
DEA  Drug  Enforcement  Administration  
DHHS  Department  of Health  and Human  Services  
DR Dose  Related  
DSM  Diagnostic  and Statistical  Manual  of Mental  Disorders  
DSM -V Diagnostic  and Statistical  Manual  of Mental  Disorders  5th Edition  
DSMB  Data  and Safety  Monitoring  Board  
ECG  Electrocardiograph  
EPIC  Electronic  Medical  Health  Records  
ET Early  Termination  
F/U Follow  Up 
FDA  Food  & Drug  Administration  
FFR Federal  Financial  Report  
Freq  Frequency  
FWA  Federal  wide  Assurance  
Study #: s22-01003   Page 7 of 64 
  GCP  Good  Clinical  Practice  
GEE  Generalized  Estimating  Equation  
GLM  General  Linear  Model  
HCG  Human  Chorionic  Gonadotropin  Pregnancy  Test 
HIPAA  Health  Insurance  Portability  and Accountability  Act of 1996  
HT  Height   
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonization  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
MAOI  Monoamine  Oxidase  Inhibitors  
MAS  Mixed  Amphetamine  Salts  
MAS  XR Mixed  Amphetamine  Salts  Extended  Release  
MHX  Medical  History  
MI Myocardial  Infarction  
MINI  Mini  International  Neuropsychiatric  Interview  
Mg Milligram  
mmHg  Millimeters  of Mercury  
MOP  Manual  of Procedures  
N Number  (typically  refers  to participants)  
NIH National  Institutes  of Health  
OHRP  Office  for Human  Research  Protections  
OHSR  Office  of Human  Subjects  Research  
PE Physical  Exam  
PI Principal  Investigator  
QA Quality  Assurance  
QC Quality  Control  
SAE Serious  Adverse  Event/Serious  Adverse  Experience  
SOP Standard  Operating  Procedure  
Serd -mph Serdexmethylphenidate  and Dexmethylphenidate   
Study #: s22-01003   Page 8 of 64 
  TASS  Time -Sensitive  ADHD  Symptom  Scale  
US United  States  
WT  Weight   
 
  
Study #: s22-01003   Page 9 of 64 
   
Protocol  Summary  
Title AN OPEN -LABEL  TREATMENT,  INVESTIGATOR -INITIATED  STUDY,  ON 
THE  DURATION  AND  EFFICACY  OF AZSTARYS 
SERDEXMETHYLPHENIDATE AND  DEXMETHYLPHENIDATE)  ON 
ADULT  ADHD SYMPTOMS  AND  EXECUTIVE FUNCTION THROUGHOUT  
THE  DAY  INTO  EARLY  EVENING  
Brief  
Summary  One purpose  of this trial is to extend  the safety  and efficacy  evidence  basis  for 
Azstarys  in adult  with  ADHD.  This open -label,  treatment study will examine  
the safety and  efficacy  of Azstarys  on ADHD symptoms  using  the AISRS 18-
item  total  score  on the AISRS-expanded; the Adult ADHD Investigator  
Symptom  Rating  Scale.  We will also  examine  Executive  Functioning  
throughout  the day to later in  the day (early  evening  -12 hours after first 
morning  dosing). 30 subjects  will be  consented  to gain 20 subjects,  which  will 
all start on  a Two-week observation  stabilization  period  for patients  before 
starting  treatment with  Azstarys.  If they are found  to have  ≥30%  change  in 
their total  AISRS (18-items)  scores  of AISRS-expanded during  the Two-week 
observation  stabilization  period, they are  discontinued  from  the study.   
 If there  is not a ≥30% change  in subject’s  18 item total  AISRS scores  of AISRS-
expanded, they will move  on to treatment of  Azstarys  and will be  dispensed  
three  weeks  of Azstarys  (flexible  dose)  starting  at 39.2 mg serd-mph/7.8 mg d-
mph up to 52.3 mg serd-mph/10.4 mg d-mph. 
 We will have  viable  data for at least  15 completers.  Subjects  will come  in 
weekly  and have th
 eir ADHD assessed  with  the AISRS EXPANDED  and CGI.  
We will assess their total  ADHD symptoms  about  twelve  hours after AM 
dosing  as measured  via total  scores  on the Time  Sensitive  Adult ADHD 
Symptom  Scale  (TASS)  and Smoothness  of Effect Scale  (AMSES)  (Three -time  
daily  on assessment  visit day) at V3, V4, V5 and V6. We will also  look at 
clinical symptoms  of Executive  Function  and emotional  dyscontrol,  as 
measured  by the BRIEF -A and ASRS -expanded at  screening baseline  start 
and end of Azstarys  dosing  epoch.   
Phase  Investigator -initiated  clinical  study  phase  4 
Objectives  The primary  objective  is to examine  the efficacy  of Azstarys  on ADHD  symptoms  
The primary  measure  of ADHD  symptoms  will be the total  score  on the AISRS  
(18 items)  of AISRS-expanded.  
 
The secondary  objectives  are to examine  changes after Azstarys  treatment in: 
1. Overall  inattentive  (IA) and hyperactive -impulsive (HI) ADHD symptom  
subsets on the AISRS EXPANDED and overall  impairment  via the 
clinical global  impression -severity (CGI -S) scale  
 
2. Clinical symptoms  of executive  function  and emotional  dyscontrol,  as 
measured  by the BRIEF -A. (BRIEF:  GEC,  metacognition,  behavioral  
regulation  scales  and subscales:  Inhibit,  Shift,  Emotional  Control,  
Study #: s22-01003   Page 10 of 64 
  Initiate,  Working  Memory,  Plan/Organize,  Organization  of Materials,  
Monitor).  
 
3. Adult ADHD Self Report Symptom  Rating Scale  (ASRS)  Symptom  
Checklist,  which  has high validity  in assessment  of core 18 adult  ADHD  
Diagnostic  and Statistical  Manual  of Mental  Disorders  (DSM)  symptoms  
and EFD  and EC symptoms.  The ASRS v1.1 Symptom  Checklist( ASRS  
31-item  scale)   is designed  to provide clinicians  with  an inventory  of adult  
ADHD symptoms  as the first part of a diagnostic  evaluation or to be used  
in monitoring  treatment response  
 
 
4. Total  ADHD symptoms  about  twelve  hours after AM dosing  as measured  
via total  scores  on the Time Sensitive  Adult  ADHD  Symptom  Scale  
(TASS)and Smoothness  of Effect Scale  (AMSES)  (3x day on assessment  
visit day;1 hour, 4 hours,  12 hours after dosing)  
 
Methodolog
y OPEN -LABEL  TREATMENT  INVESTIGATOR -INITIATED  STUDY  
Endpoint  
 
 
We will examine  potential  differential effects of Azstarys  in the sample of 
patients  who have  defined executive  dysfunctions (GEC  score  on BRIEF -A >= 
65 at baseline). We will also examine  self-report of ADHD symptoms  (on ASRS)  
versus  clinician  report (AISRS)  and changes in self-report measures of executive  
function  and emotional  dyscontrol  on the AISRS expanded, and ASRS-expanded  
versus  these  measures on the BRIEF -A. 
 
Study  
Duration  21-24 months 
Participant Duration  Subjects  will be in the study  approximately  8 weeks;  0-3 weeks  (screening)  2 
weeks  (two-week observation  stabilization  period) and 3 weeks,  open -label  
azstarys  / serdmph)  
Duration  of 
IP 
administrat
ion 3 weeks  Open -label  Azstarys  
Population Male or female between  the ages of 18-60,  inclusive,  of all races  and ethnicity,  
meeting  DSM  5-TR criteria  for a primary  diagnosis of ADHD (predominantly  
inattentive  presentation  or combined  presentation)  as diagnosed  via the Adult  
ADHD Clinicia n Diagnostic  Scale  version  1.2 (ACDS v1.2). Subjects  must  be in 
Study #: s22-01003   Page 11 of 64 
  good  health  as determined  by the principal  investigator  without  any comorbid  
psychiatric conditions  requiring  treatment for at least  2 months 
Study  Sites  NYU  
Number  of 
participants  Approximately  30 participants  expected  to be enrolled  / consent  at NYU 
Description  
of Study 
Agent  / 
Procedure  Azstarys:(SDX/d -MPH)  is FDA -approved  and contains  a molar  ratio  of 70% 
serdexmethylphenidate  (SDX), a novel  prodrug  of d-methylphenidate  (d-MPH), 
and 30% d-MPH HCl.  SDX.  It is a Schedule  II controlled substance.  
 
After a two-week stabilization -observation  period, weekly  Azstarys  will be given  
orally  starting  at 39.2 mg serd-mph/7.8 mg d-mph/day  with  titration  up to 52.3 
mg serd-mph/10.4 mg d-mph based on clinical response  and potential  adverse  
events,  for a total  of three  weeks  on Azstarys.  
Reference  
Therapy  No Reference Therapy  
Key 
Procedures  Psychological  Assessments;  MINI,  ACDS,  AISRS  EXPANDED  CGI,  CSSRS,  
ASRS-expanded, TASS,  AMSES,  BRIEF -A and Physical  Assessment  Vital  
Signs,  EKG,  Phy sical Exam  including  medical history,  UDT  and urine  
pregnancy.   
Statistical  
Analysis  For our primary  analysis,  which  uses a two-sided  test with  a type I error  of 0.05,  
it shows  that 15 evaluable  patients  will give power  of 90% or more  for effect  
sizes of 0.6 or greater.  0.6 is a reasonable  expectation  for an effect size it is half 
of the 1.2 effect size reported by Spencer  et al. 2008 and thus is at the lower  end 
of what  we should  expect  to see in this study  
  
  
 
 
 
  
 
  
 
 
 
 
Study #: s22-01003   Page 12 of 64 
  FLOW  DIAGRA M 
  
Week  0 Visit 1 Screen/Baseline 1(0-28 days) Total  N: 30 subjects  Obtain informed 
consent.  Screen potential  subjects by inclusion and exclusion criteria;  obtain history,  
document.  MINI , ACDS  v1,2,  AISRS- expanded, CGI-S, C- SSRS, ASRS -expanded, 
Psychiatric  History,  EKG, Urine Drug toxicology.  TASS (instruction),  AMSES  
(instruction),  Brief A, Physical  Exam  including Medical  History,  HT, WT, Prior/Con 
Meds,  AEs, Subject  reimbursement   
Week  1 Visit  2 (Two -week Observation  Stabilization)  - telephone  check)  No dispensation,  CM, 
CSSRS  and AE check. From  time of consent  to this visit, there  will be at least  two weeks  of observation 
stabilization  or delay  of ADHD  treatment.  Subject  reimbursement  
Week  2 Visit  3 (Open -label Treatment  with Azstarys-Initiation Dose)  Clinician Assessments (AIRSR, 
CGI, CSSRS), Vital Signs, urine pregnancy/UDT,  review  prior and con med check, Dose initiated 39.2 
mg serd-mph/7.8  mg d-mph,  TASS (3x) AMSES(3x), Brief A, Pharmacy dispensation,  Subject  
reimbursement  
Week  3 Visit  4 Flexible -Dose  Clinician  Assessments (AISRS, CGI, CSSRS),  Vital  Signs, Prior and con med 
check, Dose  adjustment 52.3 mg serd-mph/10.4 mg d-mph, TASS (3x) AMSES(3x), Pharmacy dispensation, 
Subject reimbursement  
Prior  to  
Enrollment:  
Approx.  100  
prescreened  
Week  4 Visit  5 dose  locked  Clinician  Assessments (AISRS, CGI, CSSRS),Vital  Signs, Prior and con med 
check, Dose  adjustment 52.3 mg serd-mph/10.4 mg d-mph, TASS (3x)AMSES(3x), Pharmacy dispensation, 
Subject reimbursement  
N: 20 Screen  Pass  continue  and start Two  -Week  Observation  Stabilization  period   
N; 10 Screen  Fail,  
stop  screening  
give  ADHD  
Referral  list 
Week 6 Visit 7 GCP  -Telephone  check 
AEs and Con meds Subject 
reimbursement 
Week  5 Visit  6 End  of Study (EOS)  Clinician  Assessments (AISRS, CGI, CSSRS),  Vital Signs, Prior and con 
med check, no dispensation TASS  (3x) AMSES(3x), NO Pharmacy dispensation, Subject reimbursement  

Study #: s22-01003   Page 13 of 64 
  1. Key Roles  
Principal  Investigator  
Lenard  A Adler MD 
NYU  
United  States  
Tel: 212 263-3580 
Email:  Lenard.Adler@nyulangone.org  
 
Sub-Investigator   
Marianne  T. Guschwan  MD 
NYU  
United  States  
Tel: 212 263-3580 
Email:  Marianne.Guschwan@nyulangone.org  
 Sub-Investigator  
Deepti  Anbarasan, MD 
NYU  
United  States  
212-263-3580 
Deepti.Anabarasan@nyulangone.org  
 Independent  Medical Monitor   
Donald  C. Goff, MD 
NYU  
United  States  
Tel: 646-754 -4843 
Email:  Donald.goff@nyulangone.org  
 
Key Study Personnel:  
Terry  Leon  RN, MS 
NYU  
Tel: 646-754 -4841 
Email:  Terry.Leon@nyulangone.org  
 
Corium  LLC  
 
NOTE:  No n -traditional volunteers in the study  will not interact  with subjects for research purposes.  
 
 
2. Introduction, Background  Information  and Scientific  Rationale  
 2.1. Background  Information and Relevant Literature 
Attention -deficit/hyperactivity disorder (ADHD)  is a neuropsychiatric disorder characterized by 
problems  with  sustaining  attention,  organization, planning, procrastination, daydreaming,  
restlessness,  impulsivity  and hyperactivity.  Adult ADHD is a common  and highly  impairing  disorder 
affecting  4.4%  of the US population (Kessler  RC et al. 2006). Recent factor analyses (Adler et al. 
2017)  have  highlighted  the importance  of co-travelling  symptoms  of executive  function  deficits  
(organization, planning, time mana gement  and working  memory)  in addition to the core symptoms  
Study #: s22-01003   Page 14 of 64 
  of inattention  and hyperactivity -impulsivity  noted  in the DSM  (DSM  –5) (American  Psychiatric  
Association  2013). Furthermore,  it has been  posited  that executive  function  deficits  define the 
impairment  in ADHD (Barkley  and Murphy  2010). Psychostimulants  are a mainstay  of 
pharmacotherapy  for adult  ADHD,  and five sustained release preparations  have  been  FDA  approved  
for adult  ADHD.   
 
One of these  preparations,  Serdexmethylphenidate/dexmethylphenidate  (SDX/d -MPH)  is a recently  
approved ADHD product (Azstarys)  containing  a molar  ratio  of 70% serdexmethylphenidate  (SDX),  
a novel  prodrug  of d-methylphenidate  (d-MPH), and 30% d-MPH HCl.  SDX , a Schedule  II controlled 
substance, is pharmacologically  inactive  until  gradually  converted to active  d-MPH in the lower  
intestinal  tract.  The pharmacokinetic  profile of SDX/d -MPH exhibits a singled -MPH concentration  
peak,  followed  by a gradual  elimination  curve  characterized by a long half-life  (T1/2: 11.7 hours)  
(Corium2021).   
After oral administration,  early  exposure to d-MPH is governed  primarily  by the d-MPH component,  
and mid- to late-day exposure is determined  primarily  by the gradual  conversion  of inactive  SDX  to 
active  d-MPH.  Whereas  most  once-daily  stimulant  products  utilize a formulation -based approach  to 
impart  d
elayed  and/or  ER properties,  SDX/d -MPH utilizes  a prodrug approach  to produce  a unique,  
extended -duration  pharmacokinetic  profile. A similar  approach  to prolonging  drug exposure has 
been  successfully  achieved  with the d-amphetamine  prodrug,  lisdexamfetamine (Vyvanse)  (Kollins  
et al. (2021)). 
 In the child  study,  the change  from  baseline  (predose Visit  5) in SKAMP -C scores  averaged  over the 
laboratory classroom day (Visit  6) was significantly  lower  (i.e., improved) for the SDX/d -MPH  group  
compared with  the placebo  group  (least -squares [LS] mean treatment difference [95%CI]:  -5.41 [-
7.10 to -3.71]; p < 0.001; Table  2). A post hoc analysis in which  predose Visit  6 was used  as the 
SKAMP -C baseline  resulted in similar  treatment differences for the primary  endpoint (LS mean  
treatment difference  [95%  CI]: -7.27 [-9.00 to -5.53]; p < 0.001; Table  2). Notably,  on the morning  of 
the laboratory  classroom day (Visit  6), mean  predose SKAMP -C score  change  from  baseline  was 
higher  (i.e., more  severe symptoms)  in the SDX/d -MPH group compared with  the placebo  group, a 
difference that reached  statistical  significance  (LS mean difference  [95%  CI]: 2.37 [0.07 to 4.68], p = 
0.044)  (
Kollins  et al. (2021). 
 
It would  be important to  add to the evidence basis for using  Azstarys.  The Azstarys  clinical efficacy  
data information  on overall  inattentive  (IA) and hyperactive -impulsive (HI) ADHD symptom subsets 
on the total  AISRS 18 item  of AISRS-Expanded and overall  impairment  via the clinical global  
impression -severity (CGI -S) scale.  The Clinical Global  Impression  Severity  (CGI -S) scale is a 
validated, highly  utilized  measure  of impairment  in studies  of adult  ADHD and has been  employed  
in prior ADHD studi es. In addition, adult  symptom information  will be collected using  the Time-
Sensitive  ADHD Symptom  Scale  (TASS)  and the Smoothness  of Effect Scale  (AMSES).   
 Data  from  this study will help us examine  co-travelling  symptoms  of executive  dysfunction and 
emotional  dyscontrol  by using  the ADHD symptoms  scale validated  for DSM -5 (AISRS- expanded) 
and the (BRIEF -A). We will also re-assess  ADHD clinical symptoms  later in the day via the Time-
Sensitive  ADHD Symptom  Scale  (TASS)  and Smoothness  of Effect Scale  (AMSES)  (Three times  a 
day on assess ment  visit days). 
 
Study #: s22-01003   Page 15 of 64 
  2.2. Name and Description of the Agent   
Serdexmethylphenidate/dexmethylphenidate  (SDX/d -MPH)  is a recently approved ADHD product  
(Azstarys)  containing  a molar  ratio  of 70% serdexmethylphenidate  (SDX), a novel  prodrug  of d-
methylphenidate  (d-MPH), and 30% d-MPH  HCl.  SDX,  a Schedule  II controlled substance, is 
pharmacologically  inactive  until  gradually  converted to active  d-MPH in the lower  intestinal  tract.  
The pharmacokinetic  profile of SDX/d -MPH exhibits a singled -MPH concentration  peak,  followed  by 
a gradual  elimination  curve  characterized by a long half- life (T1/2: 11.7 hours) (Corium2021). After 
oral administration, early  exposure to d-MPH is governed  primarily  by the d-MPH component,  and 
mid- to late-day exposure is determined  primarily  by the gradual  conversion  of inactive  SDX  to 
active  d-MP H.  
 
Whereas  most  once-daily  stimulant  products  utilize  a formulation -based approach  to impart  delayed  
and/or  ER properties,  SDX/d -MPH  utilizes  a prodrug approach  to produce  a unique, extended -
duration  pharmacokinetic  profile. A similar  approach  to prolonging  drug  exposure has been  
successfully  achieved  with  the d-amphetamine  prodrug,  lisdexamfetamine (Vyvanse).  (Kollins  et al. 
(2021)).  
2.2.1.  Preclinical  D
 ata 
In the child  study investigating  Azstarys;  SDX/d -MPH showed  significant  improvement  in ADHD  
symptoms  compared  with  placebo  in children  6–12 years  of age, with  a rapid onset  and extended  
duration  of treatment effect.  SDX/d -MPH was safe, with  AEs comparable  with  those  observed  with  
other  stimulant  treatments.  (Kollins  et al. (2021)) 
 
One purpose of this trial is to extend  the evidence basis for Azstarys  in adult  ADHD.  The efficacy  
data available  to date on Azstarys  is in treatment of childhood  ADHD,  although FDA approval  in 
ADHD is in age 6 and up. Given  the high prevalence  and impairment  from  adult  ADHD,  it is critical  
to gather  data as to overall  efficacy  and effects  throughout  the day of Azstarys.  Extended -release ER 
stimulants  are often  preferred because  of their duration  of effect reduced need  for multiple does 
attendance  for bette r tolerability  and decreased  potential  for abuse  and diversion  compared with  
short acting  stimulants.  (Kollins  et al. (2021), CADDRA,  (2018))  
 2.2.2.  Clinical Data to Date  
In the child  study,  the change  from  baseline  (predose Visit  5) in SKAMP -C scores  averaged  over the 
laboratory c
 lassroom day (Visit  6) was significantly  lower  (i.e., improved) for the SDX/d -MPH  group  
compared with  the placebo  group  (least -squares [LS] mean treatment difference [95%CI]:  -5.41 [-
7.10 to -3.71]; p < 0.001; Table  2). A post hoc analysis in which  predose Visit  6 was used  as the 
SKAMP -C baseline  resulted in similar  treatment differences for the primary  endpoint (LS mean  
treatment difference  [95%  CI]: -7.27 [-9.00 to -5.53]; p < 0.001; Table  2). Notab ly, on the morning  of 
the laboratory  classroom day (Visit  6), mean  predose SKAMP -C score  change  from  baseline  was 
higher  (i.e., more  severe symptoms)  in the SDX/d -MPH group compared with  the placebo  group,  a 
difference that reached  statistical  significance  (LS mean difference  [95%  CI]: 2.37 [0.07 to 4.68], p = 
0.044)  (Kollins  et al. (2021)) 
 Recent factor analyses (Adler  et al. 2017) have  highlighted  the importance  of co-travelling  symptoms  
of executive  function  deficits  (organization, planning, time management  and working  memory)  in 
addition to the core symptoms  of inattention  and hyperactivity -impulsivity  noted  in the DSM  (DSM -
5) (American  Psychiatric Association  2013). F
urthermore, it has been  posited  that executive  function  
deficits  define the impairment  in ADHD (Barkley  and Murphy  2010). Psychostimulants  are a 
Study #: s22-01003   Page 16 of 64 
  mainstay  of pharmacotherapy  and five sustained-release  preparations  have  been  FDA  approved  for 
adult  ADHD.   
 
It would  be important to  add to the evidence basis for using  Azstarys.  The Azstarys  clinical efficacy  
data information  on overall  inattentive  (IA) and hyperactive -impulsive (HI) ADHD symptom subsets 
on the AISRS Expanded  and overall  impairment  via the clinical global  impression -severity  (CGI -S) 
scale.  The Clinical Global  Impression  Severity  (CGI -S) scale is a validated, highly  utilized  measure  
of impairment  in studies  of adult  ADHD and has been  employed  in prior ADHD studies.  In addition, 
adding more adult  symptom information  using  the Time-Sensitive  ADHD Symptom  Scale  (TASS)  
and the Smoothness  of Effect Scale  (AMSES)  would  be beneficial.  
 Data  from  this study will help us examine  co-travelling  symptoms  of executive  dysfunction and 
emotional  dyscontrol  by using  the ADHD symptoms  scale validated  for DSM -5 (AISRS- expanded) 
and the (BRIEF -A). We will also re-assess  ADHD  clinical symptoms  throu ghout  the day into early  
evening  via the Time-Sensitive  ADHD Symptom  Scale  (TASS)  and Smoothness  of Effect Scale  
(AMSES)  (Three  times  daily  on assessment  visit days). 
 
2.
2.3. Dose  Rationale  
Dosing  will be  established  from  Kollins  et al. 2021 trial.  The study will not need  an IND as 
Azstarys  is approved for ages 6 and up and we are within  FDA  approved  dosing.  The recommended  
starting  dosage  of Azstarys  is 39.2 mg serdexmethylphenidate/  7.8 mg dexmethylphenidate  once 
daily  in the morning. Increase  the dosage  after one week to  a dosage  of 52.3 mg 
serdexmethylphenidate/10.4 mg dexmethylphenidate  per day. The maximum recommended  dosage  
is 52.3 mg serdexmethylphenidate/10.4 mg dexmethylphenidate  once daily.  
 
Preclinical  and Clinical Studies  
Serdexmethylphenidate  is a prodrug of dexmethylphenidate. Following  a single  dose administration  
of 52.3 mg/10.4 mg AZSTARYS and 40 mg of a dexmethylphenidate  hydrochloride  extended -release  
(ER)  capsule  in healthy  volunteers  under  fasted  conditions:  
• The mean peak plasma  concentration  (Cmax)  of dexmethylphenidate  was 14.0 ng/mL  and 
28.2 ng/mL, respectively. 
• The mean  area under  concentration curve  (AUC)  of dexmethylphenidate  was 186 
hour*ng/mL  and 248 hour*ng/mL, respectively. 
 
The plasma  PK profiles  of dexmethylphenidate  following  administration  of AZSTARYS or 
dexmethylphenidate  hydrochloride  extended -release  (ER)  capsule  
 In Adults  and Pediatric Patients  13 to 17 years  of age with  ADHD,  the efficacy  of 52.3 mg/10.4 mg 
AZSTARYS  in adults and pediatric patients  13 to 17 years  of age was established by 
pharmacokinetic  bridging  between  AZSTARYS (52.3 mg/10.4 mg) and dexmethylph enidate  
hydrochloride  extended -release  capsules.  
 2.3. Rationale  
The primary  objective  of this proposal is to extend  the efficacy  evidence  of Azstarys  in Adults  with  
ADHD.   The primary  measure  of ADHD symptoms  will be  the total  score  on the Adult ADHD 
Investigator  Symptom  Rating Scale  (AISRS)  18 item  scale.  Improvement  will be  examined  by the 
change  in AISRS between  Visit  3 Initiation  (Azstarys)  and Visit  6 End of Treatment (Azstarys). 
The Adult ADHD Investigator  Symptom  Rating Scale -expanded (AISRS)  employs  adult -stem  
Study #: s22-01003   Page 17 of 64 
  questions and rates  the 18 DSM  5 symptoms  of ADHD; Although, Azstarys  is approved  for ages 6 
and up, there  are no adult  studies  examining  efficacy just for adults.  
 
Secondary objectives  of this protocol  are to reexamine  changes after Azstarys  treatment in;  
the overall  inattentive  (IA) and hyperactive -impulsive (HI) ADHD symptom  subsets symptoms  of 
Executive  function  deficits  (EFD)  and Emotional  dysfunction(ED  )subscales on AISRS expanded 
and overall  impairment  via the Clinical Global  Impression -Severity (CGI -S) scale.   In clinical 
symptoms  of executive  function, as measured  by the BRIEF -A function  (BRIEF:  GEC,  
metacognition,  behavioral  regulation  scales and subscales:  Inhibit, Shift,  Emotional  Control,  
Initiate,  Working  Memory,  Plan/Organize, Organization of Materials,  Monitor).  Also,  subject self-
report of  symptoms  via expanded Adult ADHD Self  Report Symptom  Rating Scale  (ASRS)  
Symptom  Checklist,  which  has high validity  in assessment  of core 18 adult  ADHD Diagnostic  and 
Statistical  Manual  of Mental  Disorders  (DSM)  symptoms  and EFD  and EC symptoms.  The ASRS 
v1.1 Symptom  Checklist  (ASRS  31-item  scale)  designed  to provide clinicians  with  an inventory  of 
adult  ADHD  symptoms  as the first part of  a diagnostic  evaluation or to be used  in monitoring  
treatment response.  We will look  at the total  ADHD symptoms  about  twelve  hours after AM 
dosing  as measured  via total  scores  on the Time  Sensitive  Adult ADHD Symptom  Scale  (TASS)  
and Smoothness  of Effect Scale  (AMSES)  (done three  times  a day on assessment  visit days)  
(Spencer et  al 2008,  Ad ler et  al 2017). and in clinical symptoms  of Executive  Function and  
emotional  dyscontrol,  as measured  by the BRIEF -A and AISRS-expanded. 
 Hypotheses:  In subjects  with  adult  ADHD after 3-week Azstarys  treatment (from end of a two week 
observation  stabilization  period  to Week 5 Visit  6), there  will be  significant  improvement  in: 
1) Overall  symptoms  of adult  ADHD as measured  by the total  score  on the Adult ADHD  
Investigator  Symptom  Rating Scale  (AISRS)  (primary  effect).  
2) Overall  inattentive  (IA) and hyperactive -impulsive  (HI) ADHD symptom  subsets on the AISRS  
EXPANDED  and overall  impairment  via the clinical global  impression -severity (CGI -S) scale.  
(secondary effect).  
3)  In clinical symptoms  of Executive  Function, as measured  by the BRIEF -A. (secondary effect). 
4) In expanded Adult  ADHD Self Report Symptom  Rating  Scale  (ASRS)  Symptom  Checklist  
treatment response  (secondary  effect)  
5) Total  ADHD symptoms  twelve  hours after AM dosing  as measured  via total  scores  on the Time 
Sensitive  Adult ADHD  Symptom  Scale  (TASS)  and Smoothness  of Effects  Scale  (AMSES)  
(secondary  effect). 
 
In the child  studies  investigating  Azstarys;  SDX/d -MPH  showed  significant  improvement  in ADHD  
symptoms  com
 pared  with  placebo  in children  6–12 years  of age, with  a rapid onset  and extended  
duration  of treatment effect.  SDX/d -MPH was safe, with  AEs comparabl e with  those  observed  with  
other  stimulant  treatments.  (Kollins  et al. (2021)). 
 The efficacy  data available  to date on Azstarys  is in treatment of childhood  ADHD.  Given  the high 
prevalence  and impairment  from  adult  ADHD,  it is critical  to gather  data as to overall  efficacy  and 
effects  throughout  the day of Azstarys  in adults. Extended -release  ER stimulants  are often  preferred  
because  of their duration  of effect reduced need  for multiple  does attendance  for better tolerability  
and decreased  potential  for abuse  and diversion  compared  with  short  acting  stimulants (Kollins  et 
al. (2021), C ADDRA  (2018)). 
 
Study #: s22-01003   Page 18 of 64 
  The TASS showed  high internal  consistency and concurrent validity  with  the clinician -administered  
ADHD- RS and is a valid  and reliable  scale for measuring  change  in ADHD symptoms  over the course  
of a day in adults. (Spencer et  al 2008)  
 
The Adult ADHD Medication  Smoothness  of Effect Scale  (AMSES)  is a 6-item,  frequency -based, self-
report scale that was recently  developed  to assess the consistency  and duration  of effect  of ADHD  
medication  throughout  the day (L. A. Adler,  Lynch, Shaw, et al., 2010). The A MSES compares  the 
effectiveness  of ADHD medication  shortly after dosing  with  the effectiveness  later in the day (Adler 
et al 2017)  
 
 2.4. Potential Risks  & Benefits  
2.4.1.  Known Potential  Risks  
AZSTARYS  is a central  nervous system (CNS)  stimulant  indicated for the treatment of Attention  
Deficit  Hyperactivity  Disorder  (ADHD)  in patients  6 years  and older.  It has been  FDA -approved for 
children  6 years  of age and adults up to 65 years  of age. The most  common  adverse  events  reported  
in adult  were  decreased  appetite,  insomnia, nausea, vomiting,  dyspepsia, abdominal  pain, decreased  
weight,  anxiety, dizziness,  irritability, affect lability,  tachycardia, and increased blood  pressure.  
 AZ
STARYS  is contradicted  for patients  with  known  hypersensitivity  to serdexmethylphenidate, 
methylphenidate, or other  components  of AZSTARYS.  Bronchospasm, rash, and pruritus  have  been  
reported in patients  who received  AZSTARYS.  Hypersensitivity  reactions  such  as angioedema and 
anaphylactic  reactions  have  been  reported  in patients  treated with  other  methylphenidate  products.   
 AZSTARYS  is also contraindicated in patients  receiving  concomitant treatment with  monoamine  
oxidase  inhibitors (MAOIs), or within  14 days  following  discontinuation of treatment with  an MAOI,  
because  of the risk of hypertensive  crisis.  
 The following  adverse  reactions  have  been  associated  with  the use of amphetamines and central  
nervous system stimulants  including  AZSTARYS.  
 
1. Potential  for Abuse  and Dependence: Central  Nervous  system stimulants  including  
AZSTARYS,  other  methylphenidate -containing  products,  and amphetamines,  have  a high 
potential  for abuse. We will assess  risk of abuse  and monitor  for signs  of abuse  while  in the 
study.   
2. Cardiovascular : Sudden death, stroke and myocardial  infarction  have  been  reported in adults 
with  CNS stimulant  treatment at recommended  doses.  Sudden death  has been  reported in 
pediatric patients  with  structural  cardiac abnormalities  and other  serious  heart  problems  
taking CNS  stimulants  at recommended  doses  for ADHD.  Avoid  use in patients  with  known  
structural  cardiac abnormalities,  cardiomyopathy, serious  heart  rhythm  abnormalities,  
coronary  artery disease,  and other  serious  heart  problems.  Further,  evaluate  patients  who 
develop  exertional  chest pain, unexplained  syncope,  or arrhythmias  during  AZSTARYS  
treatment.  
3. Blood  Pressure  and Heart  Rate  Increases:  We will monitor  weekly  blood  pressure  and pulse.  
4. Priapism:  Cases of painful  and prolonged  penile erections  and priapism have  been  reported  
with  methylphenidate  products.  Immediate medical attention  should  be sought  if signs  or 
symptoms  of prolonged  penile erections  or priapism are  observed.  
Study #: s22-01003   Page 19 of 64 
  5. Peripheral  Vasculopathy, including  Raynaud's Phenomenon : Stimulants  used  to treat ADHD  
are associated  with  peripheral  vasculopathy, including  Raynaud's  phenomenon.  Careful  
observation  for digital changes is necessary  during  treatment with  ADHD stimulants.   
6. In children:  Long-term  Suppression  of Growth:  Monitor  height  and weight  at appropriate  
intervals  in pediatric patients.  
7. Psychiatric Adverse  Reactions:  Use of stimulants  may cause  psychotic  or manic  symptoms  in 
patients  with  no prior  history,  or exacerbation  of symptoms  in patients with  pre-existing  
psychiatric  illness.  We will evaluate  for bipolar  disorder using  the MINI  prior to AZSTARYS  
use. 
 
Post  marketing Experience: The following  adverse  reactions  have  been  identified  during  post 
approval use of methylphenidate  products.  Because  these  reactions  are reported voluntarily  from  
a population of uncertain  size, it is not possible  to reliably  estimate their frequency  or establish  
a causal  relationship  to drug exposure.  These adverse  reactions  are as follows:   
o Blood  and Lymphatic System  Disorders:  pancytopenia, thrombocytopenia,  
thrombocytopenic  purpura   
o Cardiac Disorders:  angina pectoris,  bradycardia, extrasystole,  supraventricular  
tachycardia, ventricular extrasystole,  palpitations,  increased heart  rate  
o Eye Disorders:  diplopia, mydriasis,  visual  impairment,  blurred vision   
o General  Disorders:  chest pain, chest discomfort,  hyperpyrexia   
o Gastrointestinal  Disorders:  dry mouth  Hepatobiliary  disorders:  hepatocellular  
injury,  acute  hepatic  failure   
o Immune  System  Disorders : hypersensitivity  reactions  such  as angioedema, 
anaphylactic  reactions,  auricular  swelling,  bullous conditions,  exfoliative conditions,  
urticarias,  pruritus  NEC,  rashes, eruptions,  and exanthemas NEC  
o Investigations:  alkaline  phosphatase  increased,  bilirubin  increased,  hepatic  enzyme  
increased,  platelet  count  decreased,  white  blood  cell count  abnormal   
o Musculoskeletal,  Connective  Tissue and Bone  Disorders:  arthralgia, myalgia,  muscle  
twitching,  rhabdomyolysis,  muscle  cramps   
o Nervous  System:  convulsion, grand  mal convulsion, dyskinesia,  serotonin  syndrome  
in combination with  serotonergic  drugs,  nervousness, headache, tremor,  drowsiness,  
vertigo   
o Psychiatric Disorders:  disorientation,  libido  changes, hallucination, hallucination  
auditory,  hallucination  visual,  logorrhea,  mania, restlessness,  agitation   
o Skin  and Subcutaneous Tissue Disorders:  alopecia, erythema,  hyperhidrosis  
o Urogenital  System:  priapism  
o Vascular  Disorders : Raynaud's phenomenon  
 
Risk  of  observation  stabilization  period: The subject  will be required to not take any ADHD  
medications  or delay start of  ADHD medication  if newly  diagnosed  and their symptoms  may return  
and or get worse.  
 
If subject is currently  prescribed ADHD  medication,  and has not taken  their medication  in past 
week,  they will be asked  not to restart their  current  medicatio n, during  this time,  their ADHD  
symptoms  may worsen.  The study doctor  and the study  staff will monitor  ADHD  symptoms  while  
subjects  are not on ADHD medications.  Subjects  are not allowed  to take any ADHD medication  other  
than Azstarys  while  in this Azstarys  trial.  
 
Study #: s22-01003   Page 20 of 64 
  Once  two-week observation  is complete,  and subjects  are still eligible  to move  to W2 Visit  3 Initiation  
Dose,  they will be prescribed Azstarys.  If subject is not eligible to move  onto W2 Visit  3, these  
subjects  are instructed by the study  clinician  to start ADHD medications  and would  be given  the 
Adult ADHD referral  list,  
 
Risk  of Safety Clinical assessments: Potential  risks  associated with  an EKG include  an initial  
feeling  of coldness  when  the test material  (sticky  pads and gel) touches the skin,  localized  rash or 
skin irritation  from  the test material.  
 
Risk  in Pregnancy:  
There  is a pregnancy  exposure registry  that monitors  pregnancy  outcomes  in women  exposed  to 
ADHD medications,  including  AZSTARYS,  during  pregnancy.  Subjects  who are pregnant, planning  
to be pregnant  or men planning  to make  a woman  pregnant  will not be eligible  for the study  and will 
not be dispensed  AZSTARYS.  
 
Because  the effect of Azstarys  on sperm  are unknown, subjects  will be required to use a medically  
accepted method  of birth  control  while  they participate  in the study and for at least  90 days  after  
the e nd  of study treatment,  using  one of the methods  described  above. If subject or their partner  
becomes  or thinks they may have  become pregnant  during  their time in the study or within  30 days  
after last dose,  we ask that they tell  the principal  investigator  right  away.  
 If found  to be pregnant  after starting  the study.  We will contact National  Pregnancy  Registry for 
Psychostimulants at 1-866-961-2388.  
 
There  are no available  data on AZSTARYS use in pregnant  women  to evaluate  for a drug-associated  
risk of major birth  defects,  miscarriage,  or other  adverse  maternal  or fetal  outcomes.  AZSTARYS  
contains dexmethylphenidate and serdexmethylphenidate,  a prodrug of dexmethylphenidate.  
Dexmethylphenidate  is the d-threo  enantiomer  of racemic methylphenidate. Published studies  and 
post marketing reports  on methylphenidate  use during  pregnancy  have  not identified  a drug-
associated  risk of major  birth  defects,  miscarr iage,  or adverse  maternal  or fetal  outcomes.  There  
may be risks  to the fetus  associated  with  the use of CNS  stimulants  use during  pregnancy  (More  
details  are covered  in the investigator ’s brochure).  
 
Patients  will be told to take medication  once daily  in the morning  and report if they have  any of 
these  e
ffects  at each  visit.  
 Risk  of loss of Confidentiality : Possible loss of confidentiality  related to urine  screens  and clinical  
data obtained  during  this study is recognized.  As a guard  against  the loss of confidentiality, all 
information  will be stored in locked  files,  which  can be accessed only by members  of the research  
staff for this project.  
 2.4.2.  Minimizing  Risks  
The above  risks  are minimized  through  standard  of care monitoring.  This monitoring  will occur 
weekly  three  times  on days  of assessments  to ensure  subject safety.  We will assess  risk of abuse  and 
monitor  for signs  of abuse  throughout  the study.  Subjects  are asked  by research  staff, how they are 
feeling  since last time at the clinic  or last phone  call. Subject will be asked  about  drugs  of abuse  at 
screening and at start of open  label  initiation  of Azstarys.  They are also asked  to supply a urine  
sample for urine drug  toxicology.  Patients  are instructed to take medication  once daily  in the 
morning  and report  if they have  any effects  at each  visit.  Subjects  are asked  three  times  throughout  
Study #: s22-01003   Page 21 of 64 
  the day at every weekly  visit regarding any adverse  events.  They are also encouraged  to reach  out 
to us even  if adverse  events  happen outside  their usual  weekly  visit.   
 
As a guard  against the loss of confidentiality,  all information  will be stored in locked  files,  in locked  
rooms,  secure  share  drive  which  can be accessed only by members  of the research  staff for this 
project.  Subjects  that are at an increased risk of phys ical or mental  harm  will be evaluated  and 
withdrawn  from  the study.  Those with  efficacy  issues  needing  treatment will be referred  to 
treatment in their community.  Women  who become pregnant  will be followed  until  birth  or 
termination  of fetus.   
 2.4.3.  Known Potential  Benefits  
Azstarys  is FDA  approved and is known  to be effective  in those  6 years  of age and older.  Azstarys  is 
used  for long term  treatment of adults with  ADHD.  While there  may not be a direct benefit  to specific  
the patients,  it is hoped  that the knowledge gained  will add to the current adult  data and benefit  
others  in the future.  If subject would  like to continue  treatment with  Azstarys,  they are able to ask 
their p
ersonal  non-study physician  for continuation of treatment.  We will do our best to 
accommodate  a seaml ess transition  to treatment with  their physician  once done  with  the study.  The 
subject is able to access  information  on accessing  Azstarys  at reduced  rates.  The Azstarys  will be 
prescribe  by their own  provider (https://azstarys-pro.com/adult-adhd ) 
 
In addition, this study will extend  the evidence basis for Azstarys  in adult  ADHD.  The efficacy data 
available  to date on Azstarys  is in treatment of childhood  ADHD,  although FDA approval in ADHD  
is in age 6 and up. Given  the high prevalence  and impairment  from  adult  ADHD,  it is critical  to 
gather  data as to overall  efficacy  and effects  throughout  the day of Azstarys.  Extended -release ER 
stimulants  are often  preferred because  of their duration  of effect reduced need  for multiple does 
attendance  for better t olerability  and decreased  potential  for abuse  and diversion  compared with  
short acting  stimulants.  (Kollins  et al. (2021), CADDRA,  2018). 
 
3. Objectives  and Purpose  
 
3.1. Primary Objective  
The primary  objective  of this proposal  is to examine  the efficacy  of Azstarys  on ADHD symptoms  
throughout  th e day into early  evening.  The primary measure  of ADHD  symptoms  will be the AISRS  
18 item  total  score  on the AISRS-expanded; the Adult ADHD Investigator  Symptom  Rating Scale.  
 3.2. Secondary  Objectives  
The secondary  objectives  of this study  are to examine  changes after Azstarys  treatment in:  
1. Overall  inattentive  (IA) and hyperactive -impulsive  (HI) ADHD  symptom subsets  on the 
AISRS  EXPANDED  and overall  impairment  via the clinical global  impression -severity (CGI -
S) scale.  
2. Total  ADHD  symptoms  about  twelve  hours after AM dosing  as measured  via total  scores  on 
the Time Sensitive  Adult ADHD Symptom  Scale  (TASS)  and Smoothness  of Effect Scale  
(AMSES)  (done three  times  a day on assessment  visit days) 
3. In clinical symptoms  of Executive  Function  and emotional  dyscontrol,  as measured  by the 
BRIEF -A and AISRS-expanded. 
 
Study #: s22-01003   Page 22 of 64 
  4. Study Design and Endpoints  
4.1. Description of Study  Design 
This is a phase  four,  two-week observation  stabilization  period, open -label, three -week treatment  
looking  at duration  and efficacy  of AZSTARY  on adults with  ADHD symptoms  and adult  executive 
functions throughout  the day into early  evening.  
 
We will introduce  a two-week observation  stabilization  lead-in to all consented  eligible  subjects.   
 Subjects,  who after two weeks  observation  stabilization,  had change  of ADHD symptoms  equal  or 
greater than  30% on total  AISRS 18 item  of AISRS-Expanded from  screening Week 1 Visit  2 to start  
of Week 2 Visit  3 will not continue  to treatment and completion  of Week 2 Visit  3. If the subject does 
not experience a 30% change  in their total  AISRS 18 item  of AISRS -Expanded scores  during  baseline  
the subject will then  continue  and initiate to a three -week open -label  treatment with  Azstarys.  
AZSTARYS  will start at dose of 39.2 mg serd-mph/7.8 mg d-mph/day  with  titration  up to 52.3 mg 
serd-mph/10.4 mg d-mph based on clinical response and  potential  adverse  events.  
 If s
ubject has experienced  a change  of 30% on total  AISRS  18 item  of AISRS-Expanded rating 
interview  subject participation  will end after the two-week  observation  period. They are given  the 
ADHD referral  list for connection  to treatment in  the community.   
  
We plan to consent  30 subjects  out of which  about  10 will screen  fail, 20 will be enrolled;  asked  to 
observation  stabilization  for two weeks,  dispensed  AZSTARY  and 15 will complete  all study visits.  
Subjects  will be seen weekly  except  for the telephone check  at Week 1 Visit  2 (Two-week stabilization  
observation). 
 
4.2. Study  Endpoints  
4.2.1.  Primary Study  Endpoints  
Our primary  outcome  is effects  on overall  adult  ADHD  symptoms  via 18 item  total  score  of AISRS-
expanded. The AISRS  18 item  total  score  of AISRS Expanded  will be will be examined  for a 30% 
change  between  the W0 Visit  1 (screening/baseline  visit)  and Week 2 Visit  3 (Initiation  Dose),   which  
happens post the two week observation  stabilization  period  and Week 5 Visit  6 (EOS  visit).  
 4.2.2.  Secondary Study Endpoints  
In secondary  analyses, we will also  analyze  the following  variables:  
• AI
SRS-expanded, evaluation of ADHD subsets IA and HI symptoms  (total,  inattentive  and 
hyperactive -impulsive subsets)and  overall  impairment  via clinical global  impression  severity  
(CGI -S) scale.   
• TASS  and AMSES  done 1 hour,  4 hours and 12 hours post dose (for effects  of Azstarys  over 
time at different points  of the day into early  evening),  
• Expanded Adult ADHD  Self Report Symptom  Rating Scale  (ASRS -expanded) Symptom  
Checklist  (total,  inattentive  and hyperactive -impulsive,  executive  function  and emotional  
control  subsets)  
• Symptoms  of executive  function  (BRIEF:  GEC,  metacognition,  behavioral  regulation  scales 
and subscales:  Inhibit, Shift,  Emotional  Control,  Initiate,  Working  Memory,  Plan/Organize,  
Organization  of Materials,  Monitor),   
• Executive  dysfunction  and emotional  dyscontrol  by using  the ADHD symptoms  scale 
validated  for DSM -5 (AISRS- expanded) and  the (BRIEF -A). 
 
Study #: s22-01003   Page 23 of 64 
  4.2.3.  Exploratory Endpoints  
We will examine  potential  differential effects  of Azstarys  in the sample of patients  who have  defined 
executive  dysfunctions (GEC  score  on BRIEF -A >= 65 at baseline).  We will also  examine  self-report  
of ADHD symptoms  (on ASRS)  versus  clinician  report (AISRS)  and changes in self-report measures  
of executive  function  and emotional  dyscontrol  on the ASRS-expanded and AISRS -expanded versus  
these  measures on the BRIEF -A. 
 
5. Study Enrollment  and Withdrawal 
5.1. Inclusion  Criteria 
In order  to be eligible  to participate  in this study,  an individual  must  meet  all of the following  
criteria:  
1. Adults  ages 18-60 years,  inclusive at the time of consent  
2. Able  to provide signed  informed  consent  
3. Any gender  
4. Subjects  with  a current primary  DSM -5 diagnosis of ADHD of predominantly  inattentive  
presentation,  or combined  presentations)  as confirmed  by the ACDS  Version  1.2.5. Subjects  
who are not receiving  any pharmacological  treatment for ADHD must  have  an AISRS 18 item  
total  score  of AISRS  expanded of ≥ 28 at screening. Subjects  who were  previously  receiving  
pharmacological  tre atment for ADHD at screening  must  have  a minimum total  AISRS 18 
item  of AISRS EXPANDED score  of ≥ 22 at screening  
5. Dysthymia  and anxiety  disorders  in remission  but stable  on psychiatric  medication  for three  
weeks  or more  at the discretion  of principal  investigator  will be allowed - medication  for these  
disorders  to remain  constant  for the duration  of the protocol . 
6. Subjects,  who have  not used  stimulant  medication  in the past 2 months.  
  
5.1.2 Exclusion Criteria  
An individual  who meets  any of the following  criteria  will be excluded  from  participation  in this 
study:  
1. Known  hypersensitivity  to serdexmethylphenidate,  methylphenidate, or product 
components.  
2. Concurrent treatment with  a monoamine  oxidase  inhibitor  (MAOI), or use of an MAOI  within  
the preceding  14 days.  
3. Lifetime bipolar  disorder, psychotic disorders,  autism,  intellectual  disability  except  mood  
disorders  accepted under  the inclusion  criteria  at the discretion  of the principal  investigator.   
4. Active  suicidality  within  past year,  or history of  suicide  attempt in  past 2 years  
5. Any history  of severe past drug  dependence determined  by the MINI  (i.e., a focus  of clinical 
attention  or a c
 ause  of substantial  social or occupational  difficulty) 
6. Concurrent  excessive  substance  abuse  and/or  history  of excessive  substance  use within  6 
months at P.I discretion/judgment  
7. Use of any prescribed benzodiazepine 
8. Any unstable  medical or  neurological  condition;  clinically  significant  medical abnormalities  
such  as cardiovascular  abnormalities,  and any chronic condition  of the central  nervous system 
9. Any psychotropic medication  usage  not approved by  P.I. 
10. Known  nonresponse  to MPH treatment  
11. History  of allergic  reaction  or sensitivity  to MPH  
12. Female of childbearing  age, who are breastfeeding, pregnant, planning  to be pregnant  or men 
planning  to make  a woman  pregnant  during  the study or for one-month  post study  
13. PI/clinician  discretion     
Study #: s22-01003   Page 24 of 64 
  5.1.3 Vulnerable Subjects  
We do not plan to enroll  any subject in  vulnerable  population.  
5.1.4   Strategies for Recruitment and Retention 
We plan to enroll  approximately  30 subjects  out of which  we anticipate  10 will screen  fail, 20 will 
initiate Azstarys  treatment,  and 15 will complete  the study.  
 
We will advertise  within  and outside  New  York  Langone  Medical Center.  We use iConnect through  
EPIC to help identify subjects.  There  are print advertisements  created and approved  to help with  
recruitment  on Studykik.   
 The Phone  Script will be used  to describe  the study to potential  subjects.  We will then  use the 
prescreen  to evaluate  eligibility.  Trained  and qualified  research  staff will conduct prescreen  in a 
private  location  and ask potential  subject if they are in an area where  they can talk about  their  
mental  and physical  health freely.  If they are not in a secure  location,  prescreen  can be conducted  
at another  time agreeable  to the subject or a redcap link can be sent instead  which  they will complete  
at their convenience.   
 
Research  Staff  will conduct the prescreen  interview  (phone/redcap) and review the collected data 
with  th
e  PI at weekly  team  meetings.  If potentially  eligible,  research  staff will schedule  the potential  
subject for the study  specific screening  visit.  The pre-screening  interview  procedures  collect the 
minimum amount  of PHI necessary  to determine  study eligibility.  Names,  dates,  phone  numbers,  
and email are required to determine  eligibility,  contact participants  regarding  their eligibility  status  
after consult  with  study  clinicians,  and to facilitate  re-contact for future  resear ch purposes 
(optional). All data is collected though secure  mechanisms,  such  as phone, WebEx  and REDCap.  
 Potential  participants  will be  asked  whether  they would  like their information  retained so they can  
be contacted for future  research  purposes. Study personnel  administering  the pre-screening  
interview  will document  opt-in  / opt-out  status in a restricted t racking log. If a subject requests  
information  regarding  opting out  of further recruitment for all research,  subjects  will be  directed to 
contact study coordinator or have  subjects  contact research -contact-optout@nyumc.org  or 1-855-777-
7858. Information  collected from  participants  who opt out of future  contact  will be destroyed  once 
the pre-screening  interview  has ended. 
 
Identifiers  from  the pre-screen  will be destroyed  if the participant  is not eligible  for a screening  visit 
unless the participant  authorizes  saving  their information  for contact regarding future  research  
opportunities.   
 
Data  for eligible  participants  will be coded  with  a unique  identifier  and stored securely  as described  
in the protocol.  
 This study will accept patient  referrals  from  other  clinicians  if the patients have  given  their treating  
physician  permission  to allow  their contact information  to be shared with  the study team.  Patients  
will be  contacted using  the methods  described above. 
 
5.1.5 Informed Consent  Process  
Informed  consent  is a process  that is initiated  prior to the individual’s  agreeing  to participate  in the 
study and continues throughout  the individual’s study participation.  Extensive  discussion  of risks  
and possible  benefits of participation  will be provided  to the participants  and their  families.  Consent  
forms  will be IRB-approved and the participant will be asked  to read and review  the document.  The 
Study #: s22-01003   Page 25 of 64 
  investigator  and/or  designee will explain  the research  study to the participant  and answer  any 
questions that may arise.  All participants  will receive  a verbal  explanation in terms  suited  to their 
comprehension  of the purposes, procedures,  and potential  risks of the study and of their rights  as 
research  participants.  Participants  will have  the opportunity to carefully  review  the written  consent  
form  and ask questions prior to signing.  The participants  should  have  the opportunity to discuss  the 
study with  their health care provider,  family  or friends prior to agreeing  to participate.  The 
participant  will sign the informed  consent  document  prior  to any procedures  being  done specifically  
for the study.  The participants  may withdraw  consent  at any time  throughout the course  of the 
study.  A copy of the signed  informed  consent  document  will be given  to the participants  for their 
records. The rights  and welfare  of the participants  will be protected by emphasizing  to them  that 
the quality  of their medical care will n ot be adversely  affected if they decline  to participate  in this 
study.  
 
A copy of the signed  informed  consent  document  will be stored  in the subject’s  research  record.  The 
consent  p rocess,  including  the name  of the individual  obtaining  consent,  will be thoroughly  
documented  in the subject’s  research  record.   
 
REMOTE  
A link to REDCap  will be emailed  to potential  subjects  after clearing  the screen.  If the potential  
subject does not want  to undergo  remote  consent  or has trouble  with  the remote  consenting  
procedures,  they will be  consented  in person  (see section  below).  
 For those  who are willing  and able to undergo  remote  consent, the research  staff will schedule  a 
Webex  meeting  with  the subject.  During  the Webex  meeting  the research  staff will explain  details  
of the study including  the risks  and benefits while  sharing  screen of the inform  consent  and asking  
page  by page if subject understands and has any questions.  Once  the subject is fully  informed  and 
does not have  any questions, they will be asked  to sign the informed  consent  via REDCap.  Once  the 
study staff has comple ted the informed  consent  process  and the subject  has signed  the consent,  the 
subject can  now proceed  with  the rest of the screening  procedures.   
 The REDCap  eConsent  link will be submitted  to the IRB for review in Research  Navigator via 
Modification  b
 efore  use in the study.  Language  consistency with  the IRB-approved consent  will be 
reviewed  and approved by the IRB before use.  
 
IN PERSON  
Potential  subjects  who are unwilling  or unable  to undergo  remote  consenting  procedures  will be 
scheduled  for an in person -screening visit.  Subjects  will be provided a copy of the ICF in person.  The 
research  staff will assist  the subject in person  how to use the WebEx  feature  on their phone  or laptop  
for future  visits with  the study doctor.   
5.1.6   Duration of Study  Participation 
Subjects  participation  in the study will last  approximately  8 weeks.  
 
5.1.7 Total Number of Participants and Sites  
This is an investigator -initiated  study.  NYU  is the only site. Recruitment will end when  
approximately  30 participants  are enrolled/signed  consent.  We expect  approximately  30 participants  
will be  enrolled  in order  to produce  15 evaluable  participants  that reach  end of treatment W5  V6. 
 
Study #: s22-01003   Page 26 of 64 
  5.2. Participant  Withdrawal  or Termination 
5.2.1.  Reasons  for Withdrawal  or Termination  
Participants  are free to withdraw  from  participation  in the study at any time upon request.  An 
investigator  may terminate  participation  in the study if: 
• Any clinical adverse  event  (AE),  laboratory  abnormality, or other  medical condition  or 
situation  occurs  such  that continued participation  in the study would  not be in the best 
interest of  the participant 
• The participant meets  an exclusion  criterion  (either  newly  developed  or not previously  
recognized)  that precludes  further study participation  
• Patients  will be withdrawn  if, in the opinion  of the study doctor,  it is no longer  safe for the 
patient  to participate  in the study.  We can get verbal  permission  to follow -up with  the patient  
in the event  they suffer adverse  events.  We will document  three  attempts  to contact the 
patient  via phone. If unable  to contact,  we will send  the patient  a certified letter.  
• The subjects  who experience ≥30%  change  in their total  AISRS-expanded;(18-item  only)  
scores  post-two -week observation  stabilization  period; Week 2 Visit  3 
 
Subjects  will enter  the two-week observation  stabilization  period  of the study,  where  they will not 
take any A DHD medications.  If they were  taking  ADHD medications,  they are asked  to stop.  If they 
are newly diagnosed with  ADHD,  they are asked  not to start any  ADHD medications.   
 
Subjects  who experience a greater than a 30% change  in their total  AISRS-expanded (18-item  only)  
scores  post-two -week observation  period; Week 2 Visit  3. are discontinued  from  the study.  We 
anticipate  that, based on the literature,  10% or fewer  of patients  will be discontinued  and that the 
overall  discontinuation  rate in the trial will be  20%.  
 Subjects  who experience an equal  or greater than 30% change  in their total  AISRS-expanded (18 –
item  only)  scores  from  Week  0 Visit  1 baseline  to  Week  2 Visit  3 (Post-Two -week Stabilization  
Period, start of Azstarys  Treatment)  will be given  ADHD Program  Referral  list and diagnostic  letter.  
Those that did not have  an equal/greater  30% change  in their AISRS-expanded (18 – item  only)  were  
continued  to open -label  Azstarys.  
 
5.2.2.  Handling  of Participant  Withdrawals  or Termination  
Patients  can withdraw  or take back  their permission  to use and share  their health information  at 
any t
ime.  When  the patient  withdraws  their permission,  they will not be able to take back  
information  that has already  been  used  or shared with  others.  In order to withdraw  their permission  
from  the study,  patients  must  send  a written  notice  to the principal  investigator  for the study noted  
on page  one of their consent  form.  If patient  withdraws  their permission,  he/she  will not be able to 
stay in this study.  
 Patients  will be withdrawn  if, in the opinion  of the study  doctor,  it is no longer  safe for the patient  
to participate  in the study.  We can get permission  to follow -up with  the patient  in the event  they 
suffer adverse  events.  We will document  three  attempts to contact  the patient  via phone  and [safe] 
email.  If unable  to contact,  we will send  the patient  a certified letter.  
 These are the possible  reasons for termination  from  the study:  
• Adverse  events   
• Lack  of efficacy   
• Lost to follow -up  
Study #: s22-01003   Page 27 of 64 
  • Pregnancy  
• Withdrawal  by subject  
• Noncompliance  
• Protocol  violation   
• Physician  discretion  
 
5.2.3 Premature Termination  or Suspension of Study 
This study may be temporarily  suspended or prematurely  terminated  if there  is sufficient  reasonable  
cause. Written  notification,  documenting  the reason  for study suspension  or termination,  will be 
provided by the suspending  or terminating  party to Corium  LLC.  If the study is prematurely  
terminated or suspended, the PI will promptly  inform  the IRB and will provide the reason(s) for the 
termination  or suspension. 
Circumstances  that may warrant  termination  or suspension  include, but are not limited  to: 
• Determination  of unexpected,  significant,  or unacceptable  risk to participants  
• Demonstration  of efficacy  that would  warrant stopping 
• Insufficient  compliance to protocol  requirements  
• Data  that are not sufficiently  complete  and/or  evaluable  
• Determination  of futility  
 
Study  may resume once concerns  about  safety,  protocol  compliance,  data quality  are addressed and  
satisfy  the Corium  LLC,  IRB and/or  FDA.  
 
6. Study Agent  (Study drug, device, biologic, vaccine etc.)  and/or  Procedural 
Intervention: AZSTARYS  (serdexmethylphenidate and d exmethylphenidate) capsules,  for oral 
use, CII [controlled substance]  
 
6.1. Study  Agent(s) and Control Description  
AZSTARYS  (serdexmethylphenidate and dexmethylphenidate) capsules,  for oral use, CII 
[controlled substance]  is a recently  approved ADHD product (Azstarys)  containing  a molar  ratio  of 
70% serdexmethylphenidate  (SDX),  a novel  prodrug  of d-methylphenidate  (d-MPH), and 30% d-
MPH HCl.  SDX,  a Schedule  II controlled substance, is pharmacologically  inactive  until  gradually  
converted to active  d-MPH in the lower  intestinal  tract.   
 Subjects  will be pick up Azstarys  capsules (serdexmethylphenidate/dexmethylphenidate): 39.2 
mg/7.8 mg, 52.3 mg/10.4 mg from  Turtle  Bay Pharmacy.  
 Azstarys  
39.2 mg/7.8  mg Capsules  – dark  blue cap/grey  body,  imprinted  with  “429” on cap and “KP415”  on the body  
52.3 mg/10.4  mg Capsules  – orange  cap/grey  body,  imprinted  with  “5612”  on cap and “KP415”  on the body  
 6.1.1.  Acquisition  
Azstarys  will be prescribed by Dr Adler or another  study doctor.  Subjects  will acquire  study 
medication  from  Turtle  Bay Pharmacy, located  at 901 2nd Ave, New  York,  NY, United  States,  New  
York  (212)  752-5151. 
 
Subject will purchase  the Azstarys  medication  with  NYU ClinCard  / Mastercard. The cost for one 
week (7 pills)  of Azstarys  is $120. The full amount  of pharmacy  cost will be added to the ClinCard  
after Dr Adler sees each  patient  and reports  the subject is  eligible for dispensation.   
Study #: s22-01003   Page 28 of 64 
   
After treatment  with  Azstarys  and completion  of study,  if requested  by subject,  there  are medication  
saving  opportunities.  Subjects  wanting  to continue  Azstarys  though their own non-study doctors  can 
find money  savings  coupons at the Azstarys  support site. https://azstarys.com/savings-and -support .  
  6.1.2.  Formulation, Appearance, Packaging, and Labeling  Azstarys  will be stored and 
dispensed  per FDA  standards  (CFR - Code  of Federal Regulations Title 21).  
 Turtle  Bay Pharmacy  is located at 901 2nd Ave, New  York,  NY, United  States,  New  York  (phone:  
212-752-5151).  6.1.3.  Product  Storage  and Stability 
Azstarys  will be stored and dispensed  from  the local  pharmacy. They will store  the drug per standard  
procedures  for controlled substances (e.g., protect from  moisture,  dispense  in tight  container).  
 6.1.4.  Preparation  
Turtle  Bay Pharmacy  will receive  Azstarys  in bulk stock  bottles  at the starting  dose of 39.2 mg serd-
mph/7.8 mg d-mph and 52.3 mg serd-mph/10.4 mg d-mph. Pharmacy  will dispense  per their  
standard  operating  procedure (SOP).  
 6.1.5.  Dosing  and Administration  
After a two-week,  observation  stabilization  
period,  all subjects  will receive  three  weeks  of treatment  with 
Azstarys  (39.2 mg serd-mph/7.8 mg d-mph–) up to 52.3 mg serd- mph/10.4 mg /day. 
 
The purpose of having  a two-week observation  period  is to exclude  subjects,  who have  highly  variable  
ADHD in or der to assess if their  improvement  is from  changes in ADHD or from  medication  effects,  
This would  limit  the exposure of  these  participants  to unnecessary research  procedures .  
 
 
6.1.6.  Route  of Administration  
Subjects  will take medication  by mouth  in the morning . Subjects  take Azstarys  capsule  at 7am +/- 
30 mins  once a day in the morning. Azstarys  can be taken  with  or without  food. Subjects  are asked  
to take Azstarys  capsule  whole  in the morning  
 6.1.7.  Starting Dose  and Dose  Escalation  Schedule  
During  the two-week observation  stabilization,  medication  is not dispensed; subjects  are required  
not to take any medication  for ADHD.  If newly diagnosed, subject not to start any medication  for 
ADHD.  
 During  Azstarys  treatment (three  weeks),  open -label  Azstarys  will be dispensed  at a dose of 39.2 mg 
serd-mph/7.8 mg d-mph/day  at Week 2 Visit  3, Initiation  Dose  - Post-Two-week Observation  
Stabilization. 
 Subjects  are titrated up (in the judgment  of the investigator)  up to 52.3 mg serd-mph/10.4 mg d-
mph/day  based  upon clinical  response  and tolerability for Week  3 visit 4. Then they will be locked  
at Week
  4 visit 5 and holding  at that dose from  (W4 V5) of up to up to 52.3 mg serd-mph/10.4 mg d-
mph at (W5 V6). At Week 5 Visit  6 there  is no dispensation  of Azstarys.  
 
Study #: s22-01003   Page 29 of 64 
  Patients  a seen weekly  throughout  the trial;  except  for Week 1 Visit  3 and Week 6 Visit  7 telephone 
check -in for safety measures.   
 
Dispensation   
• W2 V3- 39.2 mg serd-mph/7.8 mg  d-mph 
• W3 V4- up to 52.3 mg serd-mph/10.4 mg d-mph  
• W4 V5- up to 52.3 mg serd-mph/10.4 mg d-mph/hold  dose 
• W5 V6 – no dispensation   
 
Azstarys  is approved for ages 6 and up and we are within  FDA  approved  dosing.  
 
6.1.8.  Dose  Adjustments/Modifications/Delays  
All subjects  will be in an observation  stabilization  period  / not start any meds for ADHD during  this 
two-week period, if they have  not experienced  a greater than a 30% change  in their total  AISRS-
expanded(18-item  only)  scores  at Week 2 Visit  3 Initiation  Dose;  Post Observation  Stabilization  
Period , subjects  are dispensed drug  Azstarys  39.2 mg serd-mph/7.8 mg d-mph. Once  on Azstarys,  
subjects  are titrated up to 52.3 mg serd-mph/10.4 mg d-mph at the Principal  Investigator ’s 
discretion -pending efficacy  and safety.  Subjects  that experience adverse  events  (abnormal  EKG,  
abnormal  vital  signs  or any AEs that are known  to be associated  with  Azstarys)  will not be eligible  
to start the study or if they are already  in the study their dose will be held at current dosage,  or they 
will be  wi thdrawn  from  the study.   
 
6.1.9.  Duration of Therapy 
Observation  Stabilization  epoch  (two weeks),  open -label  Azstarys  treatment (three  weeks)   
 6.1.10.  Tracking of Dose  
Study  team  will review pharmacy  Standard Operating Procedures  for dispensing  of Azstarys , there  
will be a two-week observation  stabilization  lead-in and then  a three -week open -label  treatment  
with  Azstarys   
 The two- week observation  stabilization  period  starts  at the end of screening  visit after subject  
consents,  subjects  are in observation  stabilization  and will not start any medications  for ADHD.  At 
the end of the following  week;  Week 1 Visit  2 they are seen remotely  via telephone call to assess  
compliance and safety.  Subjects  return  to clinic  in one week  and dispensed  initial dose of Azstarys  
39.2 mg serd-mph/7.8 mg d-mph/day  with  titration  weekly  up to 52.3 mg serd-mph/10.4 mg d-mph 
based on clinical  respo nse and potential  adverse  events  reported and observed  at each  visit.   
 After the end of observation  stabilization  period  and start of Azstarys  period, Patients  will be seen 
weekly  throughout  the trial.  Participants  are given  dosing  instructions  and will return  to the clinic  
weekly  fo
r review  of compliance.  Subjects  must  have  over 80% compliance to continue  in the study.  
 
Compliance will be tracked by counting the remaining  pills in the bottle  at each  visit in presence  of 
patient.  Subjects  are reminded  to bring  back  their  pills and empty bottles  at each  visit.  Subjects  are 
instructed that noncompliance  without  the doctor's  approval  would  be dangerous. It may warrant  
reevaluation of their continued  participation.  
 Turtle  Bay Pharmacy  will handle  returns  as per their SOPs.  The research  team  will not be involved  
in any returns  only documenting  medication  compliance.  Pharmacy  will also dispense study 
Study #: s22-01003   Page 30 of 64 
  medication  to the subjects  weekly.  There  will be medication  compliance check  at each  visit.  Subjects  
are asked  to bring  their medication  to the visit and research  staff will count  number  of pills left in 
the bottle.  Note:  we are not taking  returns.  If there are pills in the bottle  the progress  note will 
indicate  number  of pills not taken  and the bottle  with  the extra  pills is retained by the subject.  
  
6.2. Study  Agent  Accountability  Procedures 
There  is no plan for an assignment/randomization method  after screening;  all eligible  patients  will 
go through  observation  stabilization  of current ADHD medications  and not start any for the two 
weeks.  The two weeks  of observation  stabilization -stabilization  period  is followed  by three  weeks  of 
Open -Label  Azstarys.  The Week  W1 V2, subjects  are seen remotely  via telephone call to assess  
compliance and safety.  At the start of the second  week,  (W2 V3), subjects  are dispensed  active  
Azstarys  39.2 mg serd-mph/7.8 mg d-mph/day  with  titration  weekly  up to 52.3 mg serd-mph/10.4 
mg d-mph based on clinical  response  (AISRS)  and potential  adverse  events  reported and observed  
at e ach  visit.  There  is no dispensation  for W5 V6 End of Study  Visit.   
 Corium  LLC will provide Turtle  Bay Pharmacy  the Azstarys.  Dr. Adler will prescribe  weekly  doses  
for subjects  to pick up at the local  pharmacy. Subjects  will pay for the Azstarys  themselves  from  a 
prepaid card (clinicard)  given  to them  by the study team.   
 The Azstarys  product will come  directly  from  Corium  LLC commercial  supply to Turtle  Bay 
Pharmacy . Once  the first subject is consented,  Turtle  Bay Pharmacy  will order  one stock  bottle  of 
Azstarys  that will arrive  overnight.  The Azstarys  medication  will be  on site ready for dispensation.    
 Azstarys  will be labeled  according  to the standard operating  procedures  of Turtle  Bay Pharmacy.  
Pharmacy  will reach  out to Corium  LLC for resupply. Expiry date will be included  in the stock  
bottles.  If expiry  date changes at any time,  Corium  LLC will send  us documentation  regarding  
product safety and change  of the expiry  date 
 Pharmacy  will complete  accountability  logs per their SOPS.  Additionally,  research  team  will 
document  subject dosages,  compliance in source  documentation  records.  The retail  pharmacy  will 
have  th
eir label  compliant  with  all dispensing  labeling  requirement.   
 
6.2.1.  Procedures for Training  of Clinicians  on Procedural Intervention  
All team  member  conducting  any study procedure  will have  certification  and training  to conduct the 
procedures  and have  been  deemed  competent  to perform the procedure  per the study principal  
investigator  per the delegation  logs.  
 Study  Flow  for Hybrid  Study  Visits  
 
During  Screening/Baseline Visit  (Week -3-0) 
 Screening: 
The screening  visit can be conducted hybrid  and completed  in two parts:  remote  and in-clinic.  The 
remote  screening period  can last up to 28 days. It takes  time to schedule  some  of the parts  of this 
study.  In addition, medical records  may take time to acqui re. Subjects  will be asked  to come  to the 
clinic  for physical,  EKG,  vital  signs,  urine  samples.  
  
Study #: s22-01003   Page 31 of 64 
  During  the remote  portion  of the screening  visit,  informed  consent  will be obtained  via REDCap  link 
during  a WebEx consultation  meeting  with  study  staff reviewing the inform  consent  process  of 
explaining  the study and all risks  and benefits.   
 
The informed  consent  is sent prior to the screening  WebEx  meeting  to allow  the subject time  to 
discuss with  primary  care physician  or family.  After the consent  process  is complete,  research  staff 
with  continue  with  the screening  study visit.  Study  staff will review  the inclusion  and exclusion  
criteria,  collect demographics,  medical and psychiatric history,  prior and concomitant medications,  
and confirm  no co-morbid  psychiatric  disorders  using  the MINI  and C-SSRS.  Principal  Investigator  
or trained clinician  will confirm  the ADHD diagnosis and current ADHD symptoms  via the ACDS  v 
1.2, CGI-S, AISRS-expanded  (18 item  score).  Subjects  will receive  REDCap  link to complete  a self-
assessment  of their ADHD symptoms,  expanded ASRS.  The screening/  baseline  visit can last 21 -28  
days.   
 During  the in-clinic  portion,  credentialed study staff will conduct a physical  examination, medical  
review  of systems,  vital  signs  (pulse and blood  pressure), collect  urine  sample for urine  drug screen  
/ ur
ine  pregnancy  and electrocardiogram  (ECG/EKG).  All or some  of these  clinical  examinations can 
be waived  from  the screening  process  if subject  can provide  records  from  their primary  care doctor 
done within  the past year and the principal  investigator  reviews  and approves them.  
 Baseline:  
Principal  investigator  or co-investigator  will review  all eligibility  criteria,  inclusive  of inclusion  and 
exclusion  criteria.  Any assessments  not done during  screening  will be done  before baseline  
procedures.  Study  staff will review  any new concomitant medications  or adverse  events  and clinician  
will conduct a C-SSRS.  Eligible  participant will be given  information  regarding  observation  
stabilization  period  and will be  instructed on the TASS and AMSES.   
 After all screening/baseline, procedures are completed  and the principal investigator decides  subject  
is eligible to continue  in the study, subject  will move to the two-week  stabilization- observation  phase.  
 If subject  is not eligible, their participation in the study  is complete and they will receive  the ADHD  
Referral  list that will list providers  in the community. 
 
Eligible  participants  will begin  the two-week observation  stabilization  period. Participants  will be 
instructed to an
  observation  stabilization  of current medication  and not to start any new ADHD  
medication,  if newly diagnosed.  
 
Two -week Stabilization  observation  stabilization  Phase  (Week 1, Visit  2) Telephone  check  
Research  staff will review  completion  of procedures  and assessments  from  Week 0 V1. Research  staff 
will call subject at the end of the first week to review  any changes in concomitant medications  and 
adverse  events  (AE),  if any, will be  noted.  Research  staff will call  subject for safety assessments   
 Open-label Azstarys  Treatment Phase  (Week 2, Visit  3 Hybrid  visit)  
Eligible  participants  will return  to the study  site for study assessments  and dispensation  of 
Azstarys.  The following  procedures  and assessments  will be performed  during  Visit  3: vital  signs,  
urine  pregnancy  dipstick  (for females  of childbearing  potential) , and urine  toxicology dipstick,  
AISRS,  Expanded  ASRS,  CGI-S, Concomitant  medications  and adverse  events  (AE),  if any, will be 
noted.  Participants  with  ≥30%  change  in total  AISRS-expanded  (18-item)  scores  from  Visit  1 to Visit  
3 will be discontinued  from  the study.  At the end of Visit  3, if subject  does not have  a ≥30% change  
Study #: s22-01003   Page 32 of 64 
  in total  AISRS-expanded (18-item  only)  scores.  Study  doctor will check  istop  and write  a prescription  
to local  pharmacy, who will dispense  to eligible  participants  initial dose schedule  of Azstarys.  
Subjects  will be instructed to take Azstarys  39.2mg  serdm ph/7.8d -mph the next morning, and to 
continue  to take IP once daily  in the morning. The TASS/AMES  will be done three  times  on days  of 
administration  V3, V4, V5 and V6.  
 
Treatment Phase  (Week 3-5, Visit  4-6)  
 Azstarys  Flexible  Dose  (Week 3, Visit  4 Hybrid  visit)  
Participants  will return  to the study site every  7 days  during  the AZSTARYS treatment phase. The 
following  procedures  and assessments  may be performed  at Visits  4-6: vital  signs,  AISRS-expanded, 
CGI-S, TASS/AMES,  Expanded ASRS,  C-SSRS,  Concomitant medicati ons and AEs,  if any, will be 
noted  and drug accountability  and compliance will be performed. Subjects  will receive  a re-supply of 
study medication  at the end of every  visit during  the AZSTARYS  treatment phase. The dose of 
AZSTARYS  can be clinically  adjuste d (in the judgement  of the investigator)  starting  at Visit  4 based 
upon c
linical response  and side effects,  up to a maximal dose of 52.3/10.4mg/day. Medication  
compliance will be performed  at V4, V5, and V6. Participants  must  take 80% of the prescribed dos es 
of study medication  in order  to be considered  compliant.  Subject will also complete  their Brief  A and 
expanded ASRS via remote  links.  Research  staff will check  for completion  of links.  The TASS/AMES 
will be done three  times  on days  of administration  V3, V4, V5 and V6. The recommended  dosing  is 
at 7am +/- 1 hour. The first TASS/AMES is done at half hour  to one-hour  post dose (7:30 to 8 am +/- 
1 hour), the second  TASS/AMES is done 4 hours  post dose (11am  +/- 1 hour) and the third TASS is 
done 12 hours  post dose (7 pm+/- 1 hour).  All TASS  and AMSES administrations  are completed  three  
times  daily  on assessment  visit day. Brief  A and ASRS  will be collected  either  remote or in clinic  
once a week.  
 Azstarys  Flexible  Dose  (Week 4, Visit  5 Hybrid  visit ) is the same  as Week 3 Visit  4. 
 Azstarys  Withdrawal/End  of Treatment (Visit  6) 
P
articipants  will return  to the study  site for Visit  6 within  7 days  of Visit  5. The following  procedures  
and assessments  will be performed  at Visit  6: vital  signs,  AISRS-expanded, CGI-S, TASS/AMES,  
Expanded ASRS,  C-SSRS and BRIEF -A. Concomitant medication s and AEs,  if any, will be noted  
and drug  accountability  and compliance will be performed. Participants  should  report taking  at least  
80% of the prescribed study medication  in order  to be considered  compliant.  The TASS  will be done 
three  times  on days  of administration.  The recommended  dosing  is at 7 am +/- 1 hour. The first TASS  
is done at half hour  to one-hour  post dose (7:30 to 8 am +/- 1 hour), the second  TASS is done 4 hours 
post dose (11am  +/- 1 hour) and the third TASS  is done 12 hours post dose (7 pm+/- 1 hour).  
 Participants  will be given  the Adult ADHD  Referral  list to help with  the transitioning  into treatment  
as usual.  Those that complete the study,  if requested will receive  a participation  letter that would  
include  their  diagnosis  of ADHD.  If requested  at this last visit,  the study doctor will provide subject  
a p
rescription  for one month  of off study Azstarys.  We can help with  paper work  for insurance  
authorization. Subject is no longer  in the study and will cover  cost and copayments  if any of Open  
Label  Azstarys.  
 
GCP  FOLLOWUP:  Telephone  call (visit  7) 
Study  staff will make  a phone  call to the participant within  7 days  of Visit  6 as part of good  clinical  
practices.  Patient  will be asked  about  how they are feeling.  Did they transition  into treatment as 
usual?  Concomitant medications  and AEs,  if any, will be  noted.  
Study #: s22-01003   Page 33 of 64 
   
*Unscheduled Visits approved by the principal investigator will be documented in source documents.  
These visits would  be for safety labs/EKGs,  early withdrawal  or missed  visits. 
 
6.3.  Study  Procedures / Evaluations 
Description  of the Measures are listed  below,  organized  by domain. The assessment  schedule  is 
summarized  in the schedule  of events  table  located at the end of this protocol.  These measures will 
be administered  by a trained  licensed  psychologist,  nurse, or MD.  
 Optional:  Participants  will be invited  to complete  the audio  / video  consent  form  if they consent  to 
having  their clinical interviews  video  and / or audio -recorded to ensure  clinical adherence  and to 
monitor  inter-rater reliability.  The recordings  will be stored on an MCIT -managed shared drive,  
with  no identifiers.  Subjects  will be  asked  to use a pseudo name.  
 
6.3.1.1.  Clinical Interview:  ADHD  diagnosis  and severity will be assessed  with  Adult ADHD Clinical  
Diagnostic  Scale -Version  1.2 (ACDS v1.2), a semi-structured diagnostic  interview  widely  
used  in adult  ADHD studies to evaluate  both childhood  and adult  symptoms  of ADHD, the 
Clinical Global  Impression  Scale  (CGI -S), a widely  used  clinician -rated  measure  of global 
ADHD  imp
 airment  and severity and Mini International  Neuropsychiatric Interview  (MINI)  
a short psychiatric  interview.   
 
6.3.1.2.  Mood  and ADHD:  ADHD symptoms  will also be measured  using  the Adult ADHD  
Investigator  Symptom  Rating  Scale  (AISRS)  and the 18-question  Attention  
Deficit/Hyperactivity  Disorder  Self-Report Screening  Scale  for DSM -5 (DSM -5 ASRS).  
Severity  of executive  functio n will be assessed  via the Behavioral  Rating Inventory  of 
Executive  Function - Adult version  (BRIEF -A) self-report.  Suicidality  and suicidal  ideation  
will be  assessed  via the Columbia -Suicide  Severity  Rating Scale  (C-SSRS).   
 
6.3.1.3.  Efficacy:  To evaluate  the efficacy  of Azstarys,  we will explore correlations  of TASS  and AMES  
ratings  with  AISRS expanded (18 item  score)  ratings  to examine  overall  ADHD ratings  vs. 
ADHD ratings  throughout  the day. We will assess  30% change  in BRIEF -A measures.  
Furthermore,  we will examine  potential  differential effects  of Azstarys  in the sample of 
patients  who have  defined executive  dysfunctions (GEC  score  on BRIEF -A ≥65 at baseline).  
We will also examine  correlations  in self- report of ADHD  symptoms  on the ASRS versus  
clinician  report of ADHD symptoms  on the AISRS,  and also changes in self-report measures  
of e xecutive  function  and emotional  dyscontrol  on the AISRS-expanded and  ASRS -expanded 
versus  these  measures on the BRIEF -A. 
 
Assessments  
The Adult ADHD Investigator  Symptom  Rating  Scale  (AISRS)  is an 18-item  scale,  clinician -
administered  semi-structured interview  methodology  developed  to evaluate  treatment responses  
(Spencer et al., 2010). The measure contains prompts  and stem  questions designed  to capture  the 
Diagnostic  and Statistical  Manual  of Mental  Disorders  (DSM) symptoms  of the disorder ADHD  as 
they present  in adulthood. Based  on the responses  from  the patient,  the administering  clinicians  
rate the symptom severity as 0 = none, 1 = mild,  2 = moderate,  or 3 = severe.  The scale has been  
used  and validated  many  times  in a variety  of clinical drug trials  (Adler & Gorny,  2015; Adler,  
Zimmerman,  Starr,  Silber,  Palumbo, Orman  & Spencer  2011; Goodman  et al., 2017; Spencer  et al., 
2010). The AISRS  has been  expanded to include  additional  symptoms  intended  to assess  execu tive 
function  deficits  (EFDs;  nine items)  and emotional  dyscontrol  (EC; four items).  EFDs  are deficiencies  
Study #: s22-01003   Page 34 of 64 
  of high order  cognitive  processes,  such  as self-control,  self-regulation, and ability  to prioritize  and to 
plan multiple  tasks.  EC includes symptoms  of mood  lability,  irritability,  and emotional  over-
reactivity.  These prompts  have  been  written  for the AISR S to help guide  the rater to explore the full 
manifestations of symptoms  in an adult  with  ADHD.  (Silverstein  et al. (2018)), once expanded the 
AISRS is a 34-item  scale administered  by a trained  licensed  psychologist,  nurse, or MD. 
 
The Adult ADHD Self-Report Scale  (ASRS)  Symptom  Checklist  (Expanded) is a self-report that 
presents  the 18 DSM  ADHD symptoms  in adult  context and rated  on a frequency  basis.  It was 
developed  by the World  Health  Organization (WHO)  work  group  on adult ADHD  and comprises  an 
18-item  Symptom  Checklist  (corresponding  to the 18 symptoms  found  in the DSM)  and a six-item  
screener  (items  extracted from  the symptom checklist) to help identify adults at risk of ADHD  
(Kessler  et al., 2005; Ustun  et al., 2017). The Scree ner and the Symptom  Checklist  use a 5-point 
Likert -type  scale to rate ADHD symptoms  (0 = never,  1 = rarely,  2 = sometimes,  3 = often,  and 4 = 
very o ften). Depending on the question, “sometimes,”  “often,” or “very often”  suggests  clinical 
impairment  for that specific  item.  The ASRS v1.1 Symptom  Checklist  is designed  to provide 
clinicians  with  an inventory  of adult  ADHD symptoms  as the first part of a diagnostic  evaluation or 
to be used  in monitoring  treatment  response  (Adler,  Shaw,  & Alperin,  2015; Adler et al., 2006). The 
ASRS has been  expanded to include  additional  symptoms  intended  to assess  executive  function  
deficits  (EFDs;  nine items)  and emotional  dyscontrol  (EC; four items).  EFDs  are deficiencies  of high  
order  cognitive  processes,  such  as self-control,  self-regulation,  and ability  to prioritize  and to plan 
multiple tasks.  EC includes symptoms  of mood  lability,  irritability,  and emotional  overreactivity.  
(Silverstein  et al 2018)  The subject will answer  31 questions.  Of those  31, 18 of the questions pertain  
to the 18 DSM -5 ADHD  symptoms  (ADHD Symptoms).  The expanded version  includes 9 additional 
items  that assess  Executive  Function  Deficits,  and 4 items  that assess  Emotional  Dyscontrol  
(Silverstein  et al. (2018)). The assessment  is self-administered  and completed  by subject.  
 The TASS  scale  is an 18-item  scale matching  the 18 DSM  ADHD  symptoms,  with  language  changed  
to a
llow  self-report ratings  and assessment  of ADHD symptoms  throughout  the day. It has been  
validated  and used  as a measure  of change  throughout  the day in the Spencer et al. (2008). The 
research  staff will administer  this scale.   
 Smoothness  of Effect Scale  (AMSES)  Adult ADHD Medication  Smoothness  of Effect Scale  (AMSES)  
is a 6-item,  frequency -based, self-report scale that was recently  developed  to assess  the consistency  
and duration  of effect of ADHD medication  throughout  the day (L. A. Adler,  Lynch,  Shaw, et al., 
2017). The research  staff will administer  this scale.  
 The Clinical Global  Impression  Severity (CGI -S) scale is a validated, highly  utilized  measure of 
impairment  in studies  of adult  ADHD and has been  employed  in prior ADHD  studies.  It is an 
observer -rated  scale that will be used  to measure  symptom severity.  The  investigator  or rater will 
respond  to the following  question: “Considering  your  total  clinical experience with  adult  ADHD,  how 
mentally  ill is the patient  at this time?” Response  choices  include: 1 = normal, not at all ill; 2 = 
borderline  mentally  ill; 3 = mildly  ill; 4 = moderately  ill; 5 = markedly  ill;6 = severely  ill; and 7 = 
among  th
e  most  extremely  ill patients.  (Busner  J, Targum  SD. (2007))  The scale is administered  by 
a trained licensed  psychologist,  nurse, or MD. 
 
The BRIEF -A is a 75 item  self-report scale which  is highly  validated  and normed;  it has three  major  
scales (GEC,  metacognition,  behavioral  regulation  scales  and several  subscales – see stats  section)  
– it is log transformed so scores  >=65 are considered  significant  as they are >= 1.5 SDs above  the 
population mean. The scale has been  used  as a measure  of executive  function  in several  ADHD  
Study #: s22-01003   Page 35 of 64 
  clinical trials  (Vyvanse  and Mixed  Amphetamine  Salts:  Adler LA et al. 2014; atomoxetine:  Adler LA 
et al. (2014)). This scale  is self-administered;  the subject will complete.  
 
Study  procedures  and evaluations to be done as part of the study.  All procedures  listed  here should  
be specific  to the study and not part of standard clinical care.  
Medical research  staff. 
• Medical history  will be acquired  at prescreen  and screening (mental  and physical  medical  
history will be obtained  by interview  and/or  from  medical records  if patient  has a primary  
care doctor  and agrees  to all us to contact pcp for medical records  after signing  a medical 
release  of medical  information  after consenting.)  
• Medication  history (current and past medication  taken  should  be included; prescription  and 
over-the-counter medications).  Assessment  of eligibility  should  include  a review  of permitted  
and prohibited medications.  
• Physical  examination; review  of organ  systems and vital  signs  will be done at screening  visit.  
• Echocardiogram  will be  done at screening/baseline  visit.  
• Urine  for pregnancy  (for female  subjects  of childbearing  age) and drug  screen  will be  done  
• Assessment  of study agent  adherence  via compliance questions.  
• A dministration  of questionnaires or other  instruments for patient -reported  outcomes,  either  
in the clinic  using  hard  copy questionnaires or using  redcap links.  
 6.3.2.  Standard  of Care  Study Procedures 
There  are no procedures  being  conducted as regular  standard  of care.  
 6.3.3.  Clinical Laboratory Evaluations  
Pregnancy  test and urine  toxicology  will be conducted prior to dosing.  Tests  will be conducted using  
a urine  dipstick or urine  cup. 
 Noble  Medical  19525 Janacek  Court,  Suite  104 Brookfield,  WI 53045  877- 836-5713 
info@noblemedical.com John Hlavachek  (john@noblemedical.com ) 
 
1. NMCup -12-01-BT12  PanelCup, CLIAWaived,  
AMP500/BAR300/BUP10/BZO300/COC150/MET500/MDMA500/MTD300/OPI300/OXY100/TCA1000/THC50  
2. hCG  Women  Pregnancy  Strip,  25mIU/ml, Sample:  urine. 50 strips  each  box CLIA Waived  
 
Note:  Urine Drug Screen  and Pregnancy  tests are required  within  24 hours  of study  intervention  and 
results available prior to administration of study  product  Azstarys  
 6.4. Study  Schedule  
 6.4.1.  Screening  
Prescreen Subjects  will be prescreened  with  an IRB-approved script and prescreen  form.  This prescreen  
process  will take place  either  over the telephone,  or subjects  can complete  the pre-screen  through  a 
redcap link if they prefer.  The prescreen  will take about  20 minutes to conduct and decreases  the 
burden of having  subjects  come  into the clinic  to easily  screen  fail for age, weight  or prior  
medications.  The prescreen  form  of the prescreen  failures are destroyed,  unless subject want s to opt 
Study #: s22-01003   Page 36 of 64 
  in for future  study.  Those who pass prescreen  are given  an appointment  for the hybrid  
Screening/Baseline  remote/in  clinic  visit.  Subjects  are able to opt-in  or opt out. 
 
During  Screening/Baseline Visit  (Week -3-0) Hybrid  both  remote or in clinic.  
Research  Staff  will conduct the Informed  consent  process  per clinic  standard  operating procedures  
and Inform  Consent  will be obtained  at the screening  visit before  any study procedures  are 
conducted.  Study  staff will review  the inclusion  and exclusion  criteria,  collect demographics, medical  
and psychiatric history via the MINI,  prior and concomitant medications,  vital  signs  (pulse and blood  
pressure)  and confirm  the ADHD  diagnosis  via the ACDS  v 1.2 and AISRS-expanded(18 item  score).  
Study  staff will conduct a physical  examination, medical review  of systems,  and electrocardiogram  
(ECG).  A urine  sample  will be collected for urine  drug screen  to ensure  no drugs  of abuse . Subjects  
can opt out of some  of these  tests  if they can produce medical  records  from  Primary  Care  Physician  
documenting  safety tests  completed  within  one year and the Principal  Investigator  can determine  
eligibility  based  on these  tests  and study screeni ng procedures. Participant  will complete  self-report  
forms.  
 S
creening/Baseline  Visit  (Week 0, Visit  1 Day -28 to 0)   
• Obtain informed  consent  of potential  participant verified  by signature  on written  informed  
consent  for screening  form.  
• Review  medical history to  determine  eligibility  based on inclusion/exclusion  criteria.  
• Review  medications  history to  determine  eligibility  based on inclusion/exclusion  criteria.  
• Perform  medical examinations needed  to determine  eligibility  based on inclusion/exclusion  
criteria.  
• Schedule  study visits  for participants  who are eligible and available  for the duration of the 
study.   
• Review  inclusion/exclusion  criteria.  
• Obtain urine  for toxicology  test. 
• Collect Vital  Signs  
• Confirm  Prior and  Con meds 
• Assess  any changes in healthy; New  AEs 
• CSSRS Assessed   
• Provide subject with  instructions  for dosing,  7am +/- 1 hour  and the need  to answer  
questionnaires 30mins after dosing,  4 hours after dosing  and 12 hours after dosing.  
• Provide participants  with  a copy of ICF and ClinCard  compensation.  
• Schedule  study visits  for participants  who are eligible and available  for the duration of the 
study.   
 
6.4.1.1.  Week 1 Visit  2 (Two-week Stabilization  Observation  period) - telephone check.  
Research  s taff  will call  subject for a safety check  and compliance with  study medication  regimen.  
• Confirm  Prior and  Con meds 
• Assess  any changes in healthy; New  AEs 
• C-SSRS  
 6.4.2.  Intermediate  Visits  (Post -2-week stabilization  observation  stabilization)  
 Treatment Phase: Week 2 Visit  3, Week 3 Visit  4, Week 4 Visit  5 Week 5 Visit  6. Visits  3-6 
are Hybrid  Visits.  
 
Study #: s22-01003   Page 37 of 64 
  Post-2-week observation  stabilization  period, subjects  if eligible  will continue  to treatment period  
with  Azstarys.  Week 2 Visit  3 Initiation  Dose.  Patients  who do not have  a change  of 30% or greater  
in their ADHD symptoms  will continue  in the study and will be dispensed  Azstarys  to be taken  the 
next morning.  
 
Participants  will return  to the study site every  7 days  during  the Azstarys  treatment phase. The 
following  procedures  and assessments  may be performed  at Visits  3-6: vital  signs,  AISRS expanded, 
CGI-S, TASS/AMES,  Expanded ASRS,  C-SSRS  and BRIEF -A.  
 
Concomitant medications  and AEs,  if any, will be noted  and drug  accountability  and compliance will 
be performed. Participants  must  take 80% of the prescribed doses  of study medication  in order  to be 
considered  compliant.   
 
The TASS/AMSES will be done three  times  on days  of administration.  The recommended  dosing  is 
at 7 am +/- 1 hour. The first TASS/AMSES is done at half hour  to one-hour  post dose (7:30 to 8 am 
+/- 1 hour), the second  TASS/AMSES is done 4 hours post dose (11 am +/- 1 hour) and the third  TASS  
is do ne 12 hours  post dose (7pm+/- 1 hour). All TASS/AMSES administrations  will be via telephone.  
 During  Azstarys  treatment,  participants  will receive  re-supply of study medication  at the end of 
each  visit.  Subjects  will go to Turtle  Bay Pharmacy  to pick up their medication  at V3, V4, and V5. 
 The dose is initiated  at a dose of 39.2 mg serd-mph/7.8 mg d-mph/day  at Visit  3, titrated  up (in the 
judgment  of the investigator)  up to 52.3 mg serd-mph/10.4 mg d-mph/day  based  upon clinical  
response  and tolerability  for visit 4, locked  at visit 4, and holding  at the dose from  visit 5 of up to up 
to 52.3 mg serd-mph/10.4 mg d-mph  at V6. Participants  will be instructed to bring  medication  bottle  
at each  study visit.  
 
Visit  3-6 (Days+/-1)   
• Record adverse  events  and prior/con  meds as reported by participant or observed  by 
investigator.  
• Record vital  signs,  results  of Blood  Pressure  and Pulse.  
• Research  Staff  to review  medication  compliance with  subject- ensure  80% compliance.   
• Clinician  to conduct the AISRS-expanded, CGI and CSSRS  
• P
atient  will complete  the self-questionnaires ASRS-expanded, Brief  -A 
• Clinician  to write  order  for IP Azstarys  after assessing  continued  eligibility   
• Turtle  Bay Pharmacy  to dispense Azstarys,  in accordance  with  specify procedures,  
instructions  provided to  participants.  
• Record  participant’s adherence  to treatment program.  
• Provide subject with  instructions  for dosing,  the next morning  at 7am +/- 1 hour  and the need  
to answer  questionnaires 30mins after  dosing,  4 hours after  dosing  and 12 hours after  dosing.  
• If subject miss  appointment  by one day they can have  their appointment  the following  day 
early  in the morning  and be dispensed  to take meds that morning  before 12 noon.  This is only 
done in unavoidable  circumstances  with  P.I. permission.  The deviation  woul d be documented.   
 
6.4.3.  Final Study  Visit  
Withdrawal/End  of Treatment (Visit  6) 
Study #: s22-01003   Page 38 of 64 
  This hybrid  visit will be conducted for subjects  who have  completed  their treatment at Visit  6, 
subjects  who wish  early  withdrawal  or subjects  whom  the investigator  deems  participation  is no 
longer  effective  or safe. 
 
Participants  will return  to the study  site for Visit  6 within  7 days  of Visit  5. The following  procedures  
and assessments  will be performed at Visit  6: vital  signs,  AISRS-expanded, CGI-S, TASS,  AMSES,  
Expanded ASRS,  C-SSRS and BRIEF -A. 
 
Concomitant medications  and AEs,  if any, will be noted  and drug  accountability  and compliance will 
be performed. Participants  should  report taking  at least  80% of the prescribed study  medication  in 
order  to be considered  compliant.  
 
The TASS/AMES will be done three  times  this day. The recommended  dosing  is at 7 am +/- 1 hour. 
The first TASS  is done at half hour  to one-hour  post dose (7:30 to 8 am +/- 1 hour), the second  TASS 
is done 4 hours post dose (11am  +/- 1 hour) and the third TA SS is done 12 hours  post dose (7pm+/- 
1 hour). 
  
Once  al l  assessments  and procedures  for this visit are completed,  participants  will be given  the Adult 
ADHD Referral  list to help with  the transitioning  into treatment as usual. 
 They are given  compensation  for last time per ClinCard  after the  visit is completed.  
 Those that complete  the study,  and at the principal  investigator's  discretion,  as a curtesy,  can 
request  and receive  a letter stating  their diagnosis  and their  participation  in the study.  
 Good  Clinical Practice  phone  call is conducted 7 days  after  Week  5 Visit  6. Research  staff will call 
subject to ensure  all adverse  events  have  resolved  and that they have  transitioned  into treatment  
as usual.  
 
6.4.4.  Withdrawal/Early Termination Visit  
Patients  can withdraw  or take back  their permission  to use and share  his/her  health information  at 
any time.  When  the patient  withdraws  their permission,  they will not be able to take back  
information  that has already  been  used  or shared with  others.  In order to withdraw  their permission  
from  the study,  patients  must  send  a written  notice  to the principal  investigator  for the study noted  
on page  one of their consent  form.  If patient  withdraws  their permission,  he/she  will not be able to 
stay in th
is  study.  
 
Patients  will be withdrawn  if, in the opinion  of the study  doctor,  it is no longer  safe for the patient  
to participate  in the study.  We can get verbal  permission  to follow -up with  the patient  in the event  
they suffer adverse  events.  We will document  three  attempts  to contact the patient via phone. If 
unable  to contact,  we will send  the patient  a certified letter.  (Attachment)  
 6.4.5.  Unscheduled  Visit  
Unscheduled  Visits  approved by the principal  investigator  will be documented  in source  documents.  
These visits  would  be for safety labs/EKGs, early  withdrawal  or missed  visits.  
 
6.5. Concomitant  Medications, Treatments, and Procedures 
Prior and Concomitant Therapy will be followed  throughout  the study.  Any medication  or non-
pharmacological  therapy  that is taken  by or administered  to the subject at any point during the 
Study #: s22-01003   Page 39 of 64 
  course  of the study must  be recorded in the case report form  (CRF). Subjects  will be encouraged  to 
talk with  the research  team  at each  visit to document  any new medicines,  vitamins,  and herbal  
supplements.  Azstarys  may affect the way other  medicines  work  and other  medicines  may affect 
how Azstarys  works.  Taking  Azstarys  with  other  medicines  or supplements can cause  serious side 
effects.  
 
All concomitant prescription  medications  taken  during  study participation  will be recorded on the 
case report forms  (CRFs).  For this protocol,  a prescription  medication  is defined as a medication  that 
can be prescribed only by a properly  authorized/license d clinician.  Medications  to be reported in the 
CRF  are concomitant prescription  medications,  over-the-counter medications  and non-prescription  
medications.  
 
6.5.1.  Precautionary Medications, Treatments, and Procedures 
Contraindications for participation  in this study are: 
1.  Known  hypersensitivity  to serdexmethylphenidate,  methylphenidate, or product 
components.   
2. Concurrent treatment with  a monoamine  oxidase  inhibitor  (MAOI), or use of an MAOI  within  
the preceding  14 days.  
 
6.6. Prohibited Medications, Treatments, and Procedures 
Subjects  taking stimulant  or non-stimulant  medications  for the treatment of ADHD  during  
screening  w ill be washed out for a period  equivalent  to 5 half-lives of the medication  prior to baseline 
evaluations. This would  be approximately  7-21 days  per investig ator's  decision.  
 Use of any of the following  medications  is not permitted during  the study;  unless  approved by 
investigator  and documented  in source. 
 
1. Antidepressant prescription  medication  (e.g., paroxetine,  sertraline,  venlafaxine, monoamine  
oxidase  [MAO]  blocker,  tricyclic, etc.) and St. John's Wort.  
2. Anticonvulsant  medications  (e.g., phenytoin, carbamazepine, lamotrigine,  valproic  acid,  etc.) 
and antipsychotic medication.  
3. Sedating antihistamines  (e.g., doxilamine succinate, diphenhydramine)  for use in sedation  
or aiding  with  sleep.  Subjects'  routinely  using  sedating  antihistamines  for seasonal  allergies  
will be required to switch  to non-sedating  alternatives  for the duratio n of the study,  unless 
otherwise  contraindicated. 
4. Other medications  or supplements  that may interfere  with  the assessment  of cognitive  
function  are not permitted during  the study.  
 Treatment with  any OTC or prescribed medication  will not be permitted unless discussed  with  and 
approved by  the study medical monitor/Corium  LLC/investigator.  
 Subjects  will be screened for drug and alcohol  abuse  during  the prescreen  phase. Subjects  are 
instructed on th
 e dangers of drinking  alcohol  or engaging  in drug  use during  treatment with  
Azstarys.  They  will be warned  not to use Azstarys  for any other  condition  except  the condition  for 
this study:  ADHD.  Subjects  will be instructed and reminded  at each study visit not to share  this 
medication  with  other  people,  even  if they have  ADHD.  They will be reminded  that the Azstarys  
may harm  those  for who it is not prescribed  for and it is against  the law. Subjects  will be reminded  
to report any  adverse  events  or concomitant medications  they are  taking  at each  visit.  
 
Study #: s22-01003   Page 40 of 64 
  Subjects  will be reminded  to take their medication  at 7am each  morning, as the study  assessments  
are dependent on the consumption  of Azstarys  at 7:00 am. 
 
6.7. Participant  Access  to Study  Agent  at Study  Closure 
Azstarys  is FDA approved. Subjects  will be instructed about  CoriumCares  
https://azstarys.com/savings-and -support,  to access  if eligible,  coupon  savings.  Which  are provided 
by Corium  LLC. 
 8. Assessment  of Safety 
Throughout  the study,  we will monitor  subjects  for safety and possible  pregnancy. During the 
screening and eligibility  period, we will conduct and report,  if applicable  clinical laboratory  results,  
to include  pregnancy  testing,  ECG  readings and the C-SSRS  (conducted as needed  per clinician  
discretion) if there  are significant  clinical findings.  We will monitor  subjects  weekly  for abnormal  
vital  signs,  adverse  events,  and concomitant medications.  All adverse  events  results  will be 
tabulated in manuscripts  along  with  significance testing using  the appropriate  general  linear  model.  
 Subjects  will be given  a pregnancy  contact sheet  in the event  there  is a pregnancy. The pregnant  
woman  will be given  a pregnancy  inform  consent  to read and sign to allow  us to follow -up with  the 
pregnancy  unt
 il terminated or full-term  delivery.  
 
Good  clinical practices; we will call subjects  one week after their last dose of study medication  to 
ensure  they are not experiencing  any adverse  events  and have  connected to treatment as usual  in 
the community  
 
8.1.1.  Definition  of Adverse Events  (AE)  
An adverse event  (AE)  is any symptom,  sign,  illness or experience that develops  or worsens  in 
severity during  the course  of the study.  Intercurrent illnesses  or injuries  should  be regarded as 
adverse  events.  Abnormal  results  of diagnostic  procedures  are considered  to be adverse  events  if the 
abnormality: 
• results  in study withdrawal  
• is associated  with  a serious  adverse  event  
• is associated  with  clinical signs  or symptoms  
• leads to additional  treatment or  to further diagnostic  tests  
• is considered by the investigator  to be of clinical significance  
 8.1.2.  Definition  of Serious Adverse Events  (SAE) 
 Serious Adverse Event  
Adverse  events  are classified  as serious or non-serious.  A serious adverse event  is any AE that is:  
• fatal  
• lif
e -threatening  
• requires  or prolongs  hospital  stay 
• results  in persistent  or significant  disability  or incapacity  
• a congenital  anomaly  or birth  defect 
• an important medical event  
 
Important medical events  are those  that may not be immediately  life threatening, but are clearly of 
major clinical significance.  They may jeopardize  the subject,  and may require  intervention  to prevent  
Study #: s22-01003   Page 41 of 64 
  one of the other  serious  outcomes  noted  above. For example,  drug overdose or abuse, a seizure  that 
did not result  in in-patient  hospitalization, or intensive  treatment of bronchospasm  in an emergency 
department  would  typically  be considered  serious.   
 
All adverse  events  that do not meet  any of the criteria  for serious  should  be regarded as non-serious 
adverse events.  
 
8.1.3.  Definition  of Unanticipated  Problems  (UP) 
 
Unanticipated Problems Involving  Risk  to Subjects  or Others  
Any incident,  experience,  or outcome  that meets  all of the following  criteria:   
• Unexpected  in nature, severity,  or frequency  (i.e. not described in study-related  documents  
such  as the IRB-approved protocol  or consent  form,  the investigators  brochure, etc) 
• Related  or possibly  related  to participation  in the research  (i.e. possibly  related means there  
is a reasonable  possibility  that the incident  experience,  or outcome  may have  been  caused by 
the procedures  involved  in the research)  
• Suggests  that the research  places  subjects  or others  at greater risk of harm  (including  
physical,  psychological,  economic,  or social harm). 
 
8.2. Classification of an Adverse Event  
 8.2.1.  Severity of Event  
All AEs will be assessed  by the study  clinician.  For AEs not included  in the protocol  defined grading  
system,  the following  guidelines  will be used  to describe  severity.  
• Mild  – Events  require  minimal or no treatment and do not interfere  with  the participant’s  
daily  activities.  
• Moderate – Events  result  in a low level  of inconvenience  or concern with  the therapeutic  
measures.  Moderate  events  may cause  some  interference  with  functioning. 
• Severe – Events  interrupt a participant’s  usual  daily  activity  and may require  systemic  drug  
therapy  or other  treatment.  Severe  events  are usually  potentially  life-threatening or 
incapacitating. 
 
8.2.2.  Relationship  to Study Agent  
The clinician ’s assessment  of an AE's  relationship  to study agent  (Azstarys)  is part of the 
documentation process,  but it is not a factor in determining  what  is or is not reported in the study.  
If there  is any doubt  as to whether  a clinical observation  is an AE, the event should  be reported.  All 
AEs must  have  their relationship  to study agent  assessed.   
 
Fo
r all collected AEs,  the clinician  who examines and evaluates the participant will determine  the 
AE’s causality  based on temporal  relationship  and his/her  clinical judgment.  The degree of certainty 
about  causality  will be  graded  using  the categories  below.  
• Definitely  Related  – There  is clear evidence to suggest  a causal  relationship, and other  
possible contributing  factors  can be ruled out. The clinical  event,  including  an abnormal  
laboratory test result,  occurs  in a plausible  time relationship to drug administration  and 
cannot  be explained  by concurrent disease  or other  drugs  or chemicals.  The response  to 
withdrawal  of the drug  (dechallenge) should  be clinically  plausible.  The event  must  be 
pharmacologically  or phenomenologically  definitive, with  use of a satisfactory  rechall enge  
procedure  if necessary. 
Study #: s22-01003   Page 42 of 64 
  • Probably Related – There  is evidence to suggest  a causal  relationship,  and the influence  of 
other  factors  is unlikely.  The clinical  event,  including  an abnormal  laboratory test result,  
occurs  within  a reasonable  time after  administration  of the drug,  is unlikely  to be attributed  
to concurrent disease  or other  drugs  or chemicals,  and follows  a clinically  reasonable  response  
on withdrawal  (dechallenge). Rechallenge  information  is not required to fulfill  this definition.  
• Possibly Related  – There  is some  evidence to suggest  a causal  relationship  (e.g., the event 
occurred within  a reasonable  time  after administration  of the trial medication).  However,  
other  factors  may have  contributed to the event  (e.g., the participant’s  clinical conditio n, other  
concomitant events).  Although  an AE may rate only as “possibly  related” soon after discovery,  
it can be flagged  as requiring  more  information  and later be upgraded to “probably  related”  
or “definitely  related,” as appropriate.  
• Unlikely  to be related – A clinical event,  including  an abnormal  laboratory test result,  
whose  temporal  relationship  to drug administration  makes  a causal  relationship improbable  
(e.g., the event  did not occur  within  a reasonable  time  after administration  of the trial 
medicatio n) and in wh ich other  drugs  or chemicals  or underlying  disease  provides plausible  
explanations (e.g., the participant’s  clinical condition,  other  concomitant treatments).  
• Not Related – The AE is completely  independent of study drug  administration,  and/or  
evidence exists  that the event  is definitely  related to another  etiology.  There  must  be an 
alternative,  definitive  etiology  documented  by the clinician.  
 
8.2.3.  Expectedness 
Dr. Adler and Medical Monitor  will be responsible  for determining  whether  an AE is expected  or 
unexpected.  An AE will be considered  unexpected  if the nature,  severity,  or frequency  of the event 
is not consistent with  the risk information  previously  described for the study agent. 
 8.3. Time  Period and Frequency  for Event  Assessment and Follow -Up 
The occurrence  of an AE or SAE may come  to the attention  of study  personnel  during  study visits  
and interviews  of a study  participant presenting  for medical care,  or upon review  by a study monitor.  
All AEs including  local  and systemic  reactions  not meeting  the criteria  for SAEs  will be captured on 
the appropriate RF. Information  to be collected includes event  description,  time of onset,  clinician ’s 
a 
ssessment  of severity,  relationship  to study product (assessed  only by those  with  the training  and 
authority to make  a diagnosis),  and time of resolution/stabilization  of the event.  All AEs occurring  
while  on study must  be documented  appropriately  regar dless of relationship. All AEs will be followed  
to adequate  resolution.  
 Any medical condition  that is present  at the time  that the participant  is screened  will be considered  
as baseline  and not reported as an AE. However,  if the study participant ’s condition  deteriorates  at 
any time during  the study,  it will be recorded as an AE. UPs will be recorded in the data collection  
system throughout  the study.  
 Changes in the severity  of an AE will be documented  to allow  an assessment  of the duration  of the 
event  at each  level  of severity to be performed. AEs characterized  as intermittent require  
documentation of onset  and duration  of each  episode.  
 
The PI will record  all reportable  events  with  start dates  occurring  any time after informed  consent  
is obtained  until  7 (for non-serious AEs)  or 30 days  (for SAEs)  after the last day of study  
participation.  At each  study visit,  the investigator  will inquir e about  the occurrence  of AE/SAEs  
since  the last visit.  Events  will be followed  for outcome  information  until  resolution  or stabilization.   
Study #: s22-01003   Page 43 of 64 
   
All unresolved  adverse  events  should  be followed  by the investigator  until  the events  are resolved,  
the subject is lost to follow -up, or the adverse  event  is otherwise  explained. At the last scheduled  
visit,  the investigator  should  instruct each  subject to report any subsequent  event(s)  that the subject,  
or the subject’ s personal  physician, believes  might  reasonably  be related to participation  in this 
study.  The investigator  should  notify  Corium  LLC any death  or adverse  event  occurring  at any time  
after a subject  has discontinued  or terminated  study  participation  that may reasonably  be related 
to this study.  Corium  LLC should  also be notified  if the investigator  should  become aware  of the 
development  of cancer or of a congenital  anomaly  in a subsequently  conceived  offspring of a subject  
that has participated in this study.   
 8.4. Reporting Procedures – Notifying  the IRB  
We will report any instances of unanticipated  adverse  events  or problems  with  this study to the IRB 
immediately.   
 Adverse Event  
An adverse  event  (AE)  is any symptom,  sign,  illness  or experience that develops or worsens  in 
severity  during  the course  of a study.  Inter -current illnesses  or injuries should  be regarded  as 
adverse  ev
ents.  Abnormal  results  of diagnostic  procedures  are considered  to be adverse  events  if the 
abnormality: 
• Results  in study  withdrawal  
• Is associated  with  a serious  adverse  event  
• Is associated  with  clinical signs  or symptoms  
• Leads to additional  treatment or  to further diagnostic  tests  
• Is considered by the investigator  to be of clinical significant  
 
Serious Adverse Event 
Adverse  events  are classified  as serious or non-serious.  A serious  adverse  event  (SAE)  is any AE that 
is: 
• Fatal  
• Life-threatening  
• Requires  or prolongs  hospital  stay 
• Results  in persistent  or significant  disability  or incapacity  
• A congenital  anomaly  or birth  defect 
• An important medical event   
• All adverse  events  that do not meet  any of the criteria  for serious  should  be regarded as non-
serious  adverse  events.  
 
8.4.1.  Adverse Event  Reporting 
At each  contact with  the subject,  the investigator  must  seek information  on adverse  events  by 
specific  questioning  and, as appropriate,  by examination. Information  on all adverse  events  should  
be recorded immediately  in the source  document  and in the appropriate  adverse  event  module of the 
case re port form  (CRF).  All clearly  related signs,  symptoms,  and abnormal  diagnostic  procedures  
results  should  be recorded  in the source  document  (thou gh should  be grouped  under  one diagnosis).  
All adverse  events  occurring  during  the study period  must  be recorded.  The clinical  course  of each  
event  should  be followed  until  resolution,  stabilization,  or until  it has been  determined  that the 
study treatment or participation  is not the cause.  Serious  adverse  events  that are still ongoing  at 
the end of the study period must  be followed  up to determine  the outcome.  Any serious  adverse  event  
Study #: s22-01003   Page 44 of 64 
  that occurs  after the study period  and is considered  to be possibly  related  to the study treatment or 
study participation  should  be recorded and reported immediately.  
 
For Narrative  Reports of Safety Events  
If the report is supplied  as a narrative, the minimum necessary  information  to be provided at the 
time of the initial  report includes:  
• Study  identifier  
• Study  Center  
• Subject number  
• A description  of the event  
• Date  of onset  
• Status  
• Whether  study treatment was  discontinued  
• The reason  why the event  is classified  as serious 
• Investigator  assessment  of the association  between  the event  and study treatment 
 
Investigator  Reporting: Notifying the Study Sponsor: Corium  LLC  
The following  describes  events  that must  be reported to Corium  LLC in an expedited  fashion.  
 
Initial  Report: within  24 hours:  
• The following  events  must  be reported to Corium  LLC   or  designee by email to  
dlsspvdrugsafety@eversana.com, or by eFax:  (510) 903-4260: with  copy to 
PVOperations@coirumintil.com  and coh@coriumintl.com,  within  24 hours of awareness of 
the event:  
• Unanticipated  problems  related to study participation. 
• S erious  adverse  events,  regardless  of whether  they are unexpected.  
 
Additionally,  for initial SAE notification, an FDA  Form  3500A  (MEDWATCH  Form)  must  be 
completed  by the investigator  with  all of the known  information  about  the subject and  event  and 
emailed  or faxed  to Corium  LLC, within  24 hours to CORIUM  LLC Or designee. at: 
dlsspvdrugsafety@eversana.com, with  copy to PVOperations@coirumintil.com,  and:  
 Charles  Oh MD 
Chief  Medical Officer at Corium,  LLC 
coh@coriumintl.com  
 
11 Farnsworth  Street 
4th Floor  
Boston,  MA 02210 
 
The investigator  shall  maintain a copy of the MEDWATCH  Form  on file at the study  site.  
  
 Follow -up report: within  48 hours:  
As a follow -up to the initial report,  within  the 48 hours following  the awareness of the event,  the 
investigator  shall  provide further information,  as applicable, on the unanticipated  event  or the 
unanticipated  problem  in the form  of a written  narrative.  This should  include  a copy of the IRB 
Study #: s22-01003   Page 45 of 64 
  reporting  and any other  diagnostic  information  that will assist  the understanding  of the event.  
Significant  new information  on ongoing  unanticipated  adverse  events  shall  be provided promptly to 
the study sponsor;  Corium  LLC or designee  within  48 hours of receipt,  using  the same contact  
information  as above.”  
 
Adverse Event  Reporting Period 
The study  period  during  which  adverse  events  must  be reported is normally  defined as the period  
from  the initiation  of any study procedures  to the end of the study treatment follow -up. For this 
study,  the study treatment follow -up is defined as 7 days  following the last administration  of study  
treatment.  
 Preexisting  Condition  
A preexisting  condition  is one that is present  at the start of the study.  A preexisting  condition  should  
be recorded as an adverse  event  if the frequency, intensity,  or the character of the condition  worsens  
during  the study period. 
 General  Physical  Examination  Findings 
At screening,  any clinically  significant  abnormality  should  be recorded as a preexisting  condition.  
At the end of the study,  any new clinically  significant  findings/abnormalities that meet  the definition  
of an adverse  event  must  also be recorded  and documented  as an adverse  event.  
 Post-study Adverse  Event 
All unresolved  adverse  events  should  be followed  by the investigator  until  the events  are resolved,  
the subject is lost to follow -up, or the adverse  event  is otherwise  explained. At the last scheduled  
visit,  the investigator  should  instruct each  subject to report any at the last scheduled visit,  the 
investigator  should  instruct each  subject to report any subsequent event(s)  that the subject,  or the 
subject's  personal  physician, believes  might  reasonably  be related to participation  in this study.  
 8.4.2.  Serious Adverse Event  Reporting 
Any adverse  event  that results  in hospitalization  or prolonged  hospitalization  should be documented  
and reported as a serious adverse  event  unless specifically  instructed  otherwise  in this protocol.  Any 
condition  responsible  for surgery should  be documented  as an adverse  event  if the condition  meets  
the criteria  for an adverse  event.  
 Generally,  any AE considered  serious  by the PI or Sub-investigator,  or which  meets  the definition of 
an SAE included  in Section  8.1.2, Definition  of Serious  Adverse  Event  must  be submitted  on an SAE 
form  to the Data  and Safety Monitor,  who may request  to receive real -time  notification  of all SAEs.   
 8.
4.3. Unanticipated Problem Reporting 
Incidents  or events  that meet  the OHRP  criteria  for UPs require  the creation  and completion  of an 
UP report  form.  It is the site investigator ’s responsibility  to report UPs to their IRB and Corium  
LLC. The UP report will  include  the following  information: 
• Protocol  identifying  information: protocol  title and number, PI’s name, and the IRB project  
number; 
• A detailed  description  of the event,  incident,  experience,  or outcome;  
• An explanation of the basis for determining  that the event,  incident,  experience,  or outcome  
represents  an UP; 
Study #: s22-01003   Page 46 of 64 
  • A description  of any changes to the protocol  or other  corrective  actions  that have  been  taken  
or are proposed  in response  to the UP. 
 
To satisfy  the requirement  for prompt reporting,  UPs will be reported using  the following  timeline:  
• UPs that are SAEs  will be reported to the IRB and to Corium  LLC within  48 hours of the 
investigator  becoming  aware  of the event.  
• Any other  UP will be reported to the IRB and to the  Corium  LLC within  5 working days  if 
meeting  reporting  criteria  for RNI days  of the investigator  becoming  aware  of the problem.  
• All UPs should  be reported  to appropriate  institutional  officials  (as required by an institution’s  
written  reporting  procedures),  the supporting  agency  head  (or designee),  and OHRP  if needed  
within  5 days’ timeline in accordance  with  policy  of the IR’s receipt of the report of the problem  
from  the investigator.  
 
8.4.4.  Reporting of Pregnancy  
Throughout  this study,  we will monitor  safety and possible  pregnancy  by conducting  safety clinical 
tests  during  screening  and eligibility  period. We will collect urine  pregnancy  test to ensure  safe 
participation  in th e study.  We will report to Corium  LLC a nd our IRB within  the necessary times.  
See section  on adverse  events.  In addition, we will provide pregnant  women  with  a pregnant  woman  
contact sheet  and pregnant  woman  ICF requesting  permission  to follow  pregnant  women  to 
pregnancy  outcome.  
 
8.5. Reporting Procedures – Notifying  the Study  Corium LLC 
The study clinician  will complete  a SAE Form  within  the following  timelines:  
• All deaths and immediately  life-threatening  events,  whether  related or unrelated,  will be 
recorded on the SAE Form  and submitted  to the Corium  LLC within  24 hours of site 
awareness. See Section  1, Key Roles  for contact information. 
• Other SAEs  regardless  of relationship  will be submitted  to the study Corium  LLC within  72 
hours of site awareness. 
 All SAEs  will be followed  until  satisfactory  resolution  or until  the site investigator  deems  the event  
to be chronic or the adherence  to be stable. Other supporting documentation  of the event  may be 
requested  by Corium  LLC and should  be provided as soon as possible.   
 As a follow -up to the initial report,  within  the following  48 hours of awareness of the event,  the 
investigator  shal
 l provide further information,  as applicable, on the unanticipated  event  or the 
unanticipated  problem  in the form  of a written  narrative.  This should  include  a copy of the completed  
Unanticipated  Problem  form,  and any other  diagnostic  information  that will assist  the 
understanding  of the event.  Significant  new information  on ongoing  unanticipated  adverse  effects  
shall  be provided promptly to  Corium  LLC. 
 
8.6.  Data  Safety  Monitoring  
The Principal  Investigator  (Lenard Adler,  MD) and the independent medical monitor  (Donald  Goff, 
MD) are responsible  for data safety  monitoring  reviews.   
 
Dr Goff is Director at Nathan Kline  Institute,  Marvin  Stern  Professor  and Vice Chair  for Research  
Department of Psychiatry NYU  Langone  Medical Center.  Dr. Goff.  Dr. Goff is board certified in 
psychiatry  and licensed  to practice  medicine in the state  of New  York.   
 
Study #: s22-01003   Page 47 of 64 
  He and Dr Adler will review  all the AEs,  including  those  AES listed  in section  2.4 of the protocol  on 
a quarterly basis throughout  the trial.  Drs Adler and Goff will also be responsible  to address trial-
related medical questions or problems,  and evaluate  cumulative  participant safety data and make 
recommendations  regarding  the safe continuation of the study.  . The summary  of the outcomes  of 
the safety reviews  along  with  accumulated adverse  events  and deviations will be promptly  submitted  
to Corium  LLC as well. 
 
A summary  of the outcomes  of these  safety reviews  along  with  accumulated adverse  events  and 
deviations will be submitted  to the IRB as part of an annual  progress  report  at the time  of the 
Continuing  Review  submission.  
 
8.7. Study  Halting  Rules  
The medical monitor  and Principal  Investigator  will determine  whether  the study should  be halted  
after three  severe AEs  with  probable  relationship  to the study procedures  are discovered.  The PI or 
qualified  designee will inform  the medical monitor  within  24 hours of this occurrence, cease  
screening and enrollment  of new participants,  and will provide the medical monitor  with  a list of 
AEs.  Th e medical monitor  will convene  an ad hoc meeting  by teleconference or in writing  as soon as 
possible and will provide recommendations  for proceeding  with  the study to the PI. If the medical 
monitor  finds it is likely  that the study procedures  contributed to negative  outcomes,  they will 
consider  solutions including  protocol  modifications  or potentially  terminating  the study.  
 9. Clinical Monitoring  
Clinical site monitoring  is conducted to ensure  that the rights  and well-being  of human subjects  are 
protected,  that the reported trial data are accurate, complete,  and verifiable,  and that the conduct  
of the trial follows  the currently  approved protocol/amendment(s),  with  GCP,  and with  applicable  
regulatory  requirement(s). 
• Medical Moni tor Donald  Goff MD will perform  monitoring  for this study.  
• The onsite  monitoring  will include  all Study flow data of all enrolled  subjects,  adverse  events,  
and protocol  deviations.  The monitoring  is done yearly and throughout  the study when  
needed.  
• Memo  of report is  generated  for Principal Investigator  and is shared with  the IRB.  
• NYU IRB will be provided  copies  of monitoring  reports  within  7 days  of visit.  
• D
etails  of clinical site monitoring  may be documented  in a CMP.  The CMP  describes  in detail  
who will conduct the monitoring,  at what  frequency  monitoring  will be done,  at what  level  of 
detail  monitoring  will be  performed, and the distribution  of monitoring  reports.  
 
10. Statistical  Considerations   
 
10.1.  Statistical  and Analytical  Plans  (SAP)  
Statistical  Analysis  Plan: Our primary outcome is effects  on overall  adult  ADHD symptoms  via total  
AISRS  expanded  (18 item  total)  Score.  In secondary  analyses,  we will also analyze  the following  
variables: Evaluation of ADHD subset  IA and HI symptoms  on AISRS-expanded, TASS 0.5 to 1 hour,  
4 hours and 12 hours post dose:  (total,  inattentive  and hyperactive -impulsive subsets)  (for effects  of 
AZSTARYS  over time at different points  of the day and into early  evening  ); expanded Adult ADHD  
Self Report Scale  (ASRS ) Symptom  Checklist  (total,  inattentive  and hyperactive -impulsive,  
executive  function  and emotional  control  subsets);  symptoms  of executive  function  (BRIEF -A: GEC,  
metacognition,  behavioral  regulation  scales  and subscales:  Inhibit, Shift,  Emotional  Control , 
Initiate,  Working  Memory,  Plan/Organize, Organization of Materials,  Monitor)  
Study #: s22-01003   Page 48 of 64 
   
Our statistical  analysis framework  will be the general  linear  regression  model.  We will choose the 
distributional  family  and link function  based on the distribution  of the outcome  variables. Each  
regression  model  will predict the outcome  as the dependent v ariable  with  weeks  in trial after the 
end of the open -label  as the independent variable. All analyses will use the ITT sample.  For our 
design,  a significant  effect of week assesses  the significance  of the drug effect.  We have  chosen  an 
IIT analyses as we can include  all patients  except  for subjects  who have  experienced  a greater than  
a 30% change  in their total  AISRS-expanded (18-item)  scores  during  baseline  in the analyses.  These  
patients  who experience ≥30%  change  in their total  AISRS –expanded (18 items ) scores  during  two 
weeks  observation  stabilization  period  will be discontinued  from  the protocol.  We anticipate  that,  
based on the literature,  10% or fewer  of patients  will have  the 30% change  in their  AISRS-expanded  
(18-item  only)  scores  from screening  to end of observation  stabilization  period  and that the overall 
discontinuation rate in the trial will be 20%. Changes within  the day in TASS/AMES ratings  0.5 to 
1-hour  post dose vs. 4-hour  post dose vs. 12 hours post dose will also be analyzed via the general  
linear  regression  model.  Correlations  between  ADHD  and executive  function  ratings  will be 
examined  via Spearman's correlation coefficients.  
 
Exploratory  Objectives:  We will explore correlations  of TASS/AMES  ratings  with  AISRS-expanded 
ratings  to examine  overall  ADHD ratings  vs. ADHD ratings  throughout  the day. We will look at 
changes in BRIEF -A measures throughout  the study.  Furthermore,  we will examine  potential  
differential effects  of Azstarys  in the sample of patients  who have  defined executive  dysfunctions  
(GEC  score  on BRIEF - A >= 65 at baseline).  We will also examine  correlations  in self-report of ADHD  
symptoms  on the ASRS)  versus  clinician  report of ADHD symptoms  on the AISRS,  and also changes  
in self-report  measure s of executive  function  and emotional  dyscontrol  on the ASRS expanded versus  
these  measures on the BRIEF -A. 
 
10.2.  Description of Statistical  Methods 
Our primary  outcome  is effects  on overall  adult  ADHD symptoms  via total  Expanded AISRS (18-
item  only)  Score,  assessing  executive  function  deficits  (EFDs;  nine items)  and emotional  dyscontrol  
(EC; fo ur items).  EFDs  are deficiencies of high order  cognitive  processes,  such  as self-control,  self-
regulation, and ability  to prioritize  and to plan multiple  tasks.  EC includes symptoms  of mood  
lability,  irritability,  and emotional  overreactivity. These prompts  have  been  written  for the AISRS-
expanded to help guide  the rater to explore the full manifestations  of symptoms  in an adult  with  
ADHD.  (Silverstein  et al 2018).  
 
In secondary  analyses, we will also analyze  the following  variables: Evaluation of ADHD subset  IA 
and HI symptoms  on AISRS,  and TASS/AMES 0.5 to 1 hour, 4 hours and 12 hours post dose:  (total,  
inattentive  and hyperactive -impulsive subsets) (for effects  of Azstarys  over time at different points  
of the day and within  the day), expanded Adult ADHD Self Report Symptom  Rating Scale  (ASRS)  
Symptom  Checklist  (total,  inattentive  and hyperactive -impulsive,  executive  function  and emotional  
control  subsets),  symptoms  of executive  function  (BRIEF:  GEC,  metacognition, behavioral  
regulation  scales and subscales:  Inhibit, Shift,  Emotional  Control,  Initiate,  Working  Memory,  
Plan/Organize, Organization of Materials,  Monitor),  executive  dysfunction and emotional  dyscontrol  
by using  the ADHD symptoms  scale validated  for DSM -5 (AISRS- expanded) and the (BRIEF -A).  
 Ou
r statistical  analysis framework  will be the general  linear  regression  model.  We will choose the 
distributional  family  and link function  based on the distribution  of the outcome  variables. Each  
regression  model  will predict the outcome  as the dependent v ariable  with  weeks  in trial after the 
end of the open -label  as the independent variable. All analyses will use the ITT sample.  For our 
Study #: s22-01003   Page 49 of 64 
  design,  a significant  effect of week assesses  the significance  of the drug effect.  We have  chosen  an 
IIT analyses as we can include  all patients  except  for Subjects  who experience a 30% change  in 
AISRS-expanded  (18-item  only in the analyses. We have  chosen  to exclude  those  patients  that 
experience greater than  a 30% change  in their total  AISRS-expanded (18-item  only)  scores  during  
open -label  treatment and will discontinue  them  from  the protocol.  We anticipate  that based on the 
literature  that 10% or fewer  of patients  will have  the 30% change  in AISRS-expanded (18-item  only)  
and that the overall  discontinuation rate in the trial will be 20%.  Changes within  the day in 
TASS/AMES ratings  0.5 to 1-hour  post dose vs. 4-hour  post dose vs. 12 hours post dose will also be 
analyzed via the general  linear  regres sion model.  Correlations  between  ADHD  and executive  
function  ratings will be  examined  via Spearman ’s correlation coefficients.  
 
10.2.1.  Analysis  of the Primary Efficacy Endpoint(s)   
Our primary  outcome  is effects  on overall  adult  ADHD symptoms  via total  Expanded AISRS (18-
item)  S core,  assessing  executive  function  deficits (EFDs;  nine items)  and emotional  dyscontrol  (EC; 
four items).  EFDs  are deficiencies  of high order  cognitive  proces ses, such  as self-control,  self-
regulation, and ability  to prioritize  and to plan multiple  tasks.  EC includes symptoms  of mood  
lability,  irritability,  and emotional  overreactivity. These prompts  have  been  written  for the AISRS-
expanded to help guide  the rater to explore the full manifestations  of symptoms  in an adult  with  
ADHD.  (Silverstein  et al 2018)  
 
Missing  outcome data will be handled  in regards  to analysis in the following  way:  last observation  
will be  carried forward.  
 
10.2.2.  Analysis  of the Secondary Endpoint(s)  
In secondary  analyses, we will also analyze  the following  variables: Evaluation of ADHD subset  IA 
and HI symptoms  on AISRS-expanded, and TASS/AMES  0.5 to 1 hour, 4 hours and 12 hours post 
dose:  (total,  inattentive  and hyperactive -impulsive  subsets)  (for effects  of Azstarys  over time  at 
different points  of the day and within  the day), expanded Adult ADHD Self Report Symptom  Rating  
Scale  (ASRS)  Symptom  Checklist  (total,  inattentive  and hyperactive -impulsive,  executive  function  
and emotional  control  subsets)  , symptoms  of executive  function  (BRIEF:  GEC,  metacognition,  
behavioral  re gulation  scales and subscales:  Inhibit, Shift,  Emotional  Control,  Initiate,  Working  
Memory,  Plan/Organize, Organization  of Materials,  Monitor),  executive  dysfunction and emotional  
dyscontrol  by using  the ADHD symptoms  scale validated for DSM -5 (AISRS- expanded)(ASRS-
expanded) and the (BRIEF -A).  
 
Our statistical  analysis framework  will be the general  linear  regression  model.  We will choose the 
distributional  family  and link function  based on the distribution  of the outcome  variables. Each  
regression  model  will predict the outcome  as the dependent v ariable  with  weeks  in trial after the 
end of the open -label  as the independent variable. All analyses will use the ITT sample.  For our 
design,  a significant  effect of week assesses  the significance  of the drug effect.  We have  chosen  an 
IIT analyses as we can include  all patients  except  for Subjects  who experience a 30% change  in 
AISRS-expanded  (18-items)  in the analyses. We have  chosen  an open -label  and will not include  in 
the open - label  treatment subjects   who experience greater than a 30% change  in their  total  AISRS-
expanded(18-item)scores  during  two-week observation  period. We anticipate  that based on the 
literature  t hat 10% or fewer  of patients  will be excluded. for having  the 30% change  in AISRS-
expanded(18-item)  at baseline  prior  to open -label  treatment and the overall  discontinuation  rate in 
the trial will be 20%. Changes within  the day in TASS  ratings 0.5 -1-hour  post dose vs. 4-hour  post 
dose vs. 12 hours post dose will also be analyzed via the general  linear  regression  model.  Correlations  
Study #: s22-01003   Page 50 of 64 
  between  ADHD and executive  function  ratings will be examined  via Spearman’ s correlation 
coefficients.  
 
10.2.3.  Safety Analyses  
 Primary  Objective:  The primary  objective  of this proposal is to examine  the efficacy  of Azstarys  on 
ADHD symptoms  and Executive  Function. The primary  measure  of ADHD symptoms  will be the 
total  score  on the AISRS-expanded (18-items) . 
 Secondary  Objective(s):  To examine  changes after Azstarys  treatment in: 2) overall  inattentive  (IA) 
and hyperactive -impulsive (HI) ADHD symptom  subsets on the AISRS- expanded and overall  
impairment  via the clinical  global  impression -severity (CGI -S) scale.; 3) total  ADHD  symptoms  
about  twelve  hours after AM dosing  as measured  via total  scores  on the Time Sensitive  Adult  ADHD  
Symptom  Scale  (TASS)and  Smoothness  of Effect Scale  (AMSES)  (Three  times  daily  on assessment  
visit day) ; and 4) in clinical symptoms  of Executive  Function  and emotional  dyscontrol,  as measured  
by the BRIEF -A and AISRS-expanded. 
 Exploratory  Objectives:  We will examine  potential  differential effects  of Azstarys  in the sample  of 
patients  who have  defined executive  dysfunctions (GEC  score  on BRIEF -A >= 65 at    baseline). We 
will a
lso  examine  self-report  of ADHD symptoms  (on ASRS)  versus clinician  report (AISRS)  and also 
changes in self-report measures of executive  function  and emotional  dyscontrol  on the ASRS  versus  
these  measures on the BRIEF -A. 
 
10.2.4.  Adherence and Retention  Analyses  
Research  staff will ensure  subject adhere  to the study visit schedule  by confirming  appointments at 
each  visit.  Subjects  will adhere  to the medication  schedule  by conducting  compliance  check  at each  
visit.  Subjects  are asked  to have  at least  80% compliance. Subjects  will be contacted three  times  via 
telephone/email  if subject misses  a visit.  If no response  there  will be an approved IRB certified letter 
sent to the subject.  All will be  documented  in subject source  document  folder. If subject misses  visit 
and are non-compliant  their participation  will be assessed  by study doctor.  Principal  investigator  
can discontinue  subject per his discretion.   
 
10.2.5.  Planned  Interim Analysis  
Not applicable,  interim  analysis not planned at this time  
 10.3.  Sample  Size 
Up to 30 patients  will be screened,  20 enrolled  (two-week observation  stabilization  period), 
approximately  20 patients  to be Enrolled  (Azstarys),  to be sure that 15 evaluable  patients  reach  the 
end of tre
atment at week  five. The graph  shows power  at different values of the Cohen ’s d effect  size 
for estimating  the difference between  baseline  and endpoint values. For our primary  analysis,  which  
uses a two-sided  test with  a type I error of 0.05, it shows  that 15 evaluable  patients  will give power  
of 90% or more  for effect sizes of 0.6 or greater.  0.6 is a reasonable  expectation  for an effect size it is 
half of the 1.2 effect size reported by Spencer  et al. 2008 and thus is at the lower  end of what  we 
should  expect  to see in this study.  We believe  that the power  will be slightly  higher  in direct 
comparison  vs. Spencer  as that study was parallel  group  placebo  controlled.  The use of eliminating  
subject with  a change  of 30% or greater in their AISRS-expanded between   screening  to end of two 
week prior to open  label  treatment period  should  increase  the power  somewhat  in this trial in terms  
of direct comparison.   
 
Study #: s22-01003   Page 51 of 64 
  11. Source Documents  and Access  to Source Data/Documents  
Source  data is all information, original  records  of clinical findings,  observations, or other  activities  
in a clinical trial necessary  for the reconstruction and evaluation of the trial.  Source  data are 
contained  in source  documents.  Examples  of these  original documents,  and data records  include:  
hospital  records,  clinical and office  charts,  laboratory notes,  memoranda, subjects  ’diaries  or 
evaluation checklists,  pharmacy  dispensing  records, recorded  data from  automated instruments,  
copies  or transcriptions  certified after verification  as being  accurate  and complete,  microfiches,  
photographic negatives,  microfilm or magnetic  media,  x-rays,  subject  files,  and records  kept at the 
pharmacy, at the laboratories,  and at medico -technical  departments  involved  in the clinical trial.  It 
is acceptable  to use CRFs  as source  documents.  If this is the case,  it should  be stated  in this section  
what data will be  collected on CRFs  and what  data will be  collected from  other  sources.  
 
The study case report form  (CRF)  is the primary  data collection  instrument  for the study.  All data 
requested  on the CRF  must  be recorded.  All missing  data must  be explained. If a space  on the CRF  
is l eft blank  because  the procedure  was not done or the ques tion was not asked,  write  “N/D”.  If the 
item  is not applicable  to the individual  case,  write  “N/A”.  All entries  should  be printed  legibly  in 
black  ink. If any entry  error has been  made, to correct such  an error,  draw  a single  straight line 
through  the incorrect entry and enter  the correct data above  it. All such  changes must  be initialed  
and dated. DO NOT  ERASE OR WHITE  OUT  ERRORS.  For clarification  of illegible or uncertain  
entries,  print the  clarification above  the item,  then  initial and date it. 
 
Access  to study records  will be limited  to IRB-approved members  of the study team.  The investigator  
will permit  study-related  monitoring,  audits, and inspections  by the IRB/EC,  the Corium  LLC, 
government regulatory  bodies,  and University  compliance and quality  assurance  groups  of all study  
related documents  (e.g. source  documents, regulatory  documents,  data collection  instruments,  study  
data etc.).  The investigator  will ensure  the capability  for inspections  of applicable  study-related 
facilities  (e.g. pharm acy, diagnostic  laboratory,  etc.).  
 Participation  as an investigator  in this study implies  acceptance  of potential  inspection  by 
government re
 gulatory  authorities  and applicable  University  compliance  and quality  assurance  
offices.  
12. Quality  Assurance  and Quality  Control  
The principal  investigator  has ethical,  legal,  and scientific  obligations to follow  this trial in 
accordance  with  established research  principles,  the ICH E6 GCP:  Consolidated  Guidance, and 
applicable  regulatory  requirements and local  laws.  The investigator will ensure  all research  staff 
working  on this protocol  meet  the acceptance  of the IRB.  In addition, all investigators  and clinical  
site personnel  will undergo  initial and ongoing  training  for this clinical trial.  The training  will be 
documented  on train ing logs.  
 Either institution  or senior  research  staff may conduct quality  assurance  audits. Audits  will include,  
but are not limited  to IMP supply, presence  of required documents,  the informed  consent  process,  
and comparison  of the data in REDCap  against  the paper source  documents.  The senior  research  
staff, investigator  or co-investigator  will also  spot check  charts,  REDCap,  and sign off on completed  
subjects.  
 
During  each subject's  visit to the clinic,  research  staff will record  progress  notes  to document  all 
significant  observations. The investigator  or co-investigator  will sign  these  notes  at each  visit.  
Study #: s22-01003   Page 52 of 64 
  At a minimum,  these  notes  will contain  documentation  of the informed  consent  process,  any revised  
consents,  eligibility  (inclusion/exclusion  criteria  prior to study medication  administration),  date of 
the visit and the corresponding visit in the trial schedule. The note will also include  the presence  or 
absence  of adverse  events  (severity,  frequency, duration,  action  taken, outcome  and relationship  to 
study medication  as assessed  by the investigator/co -investigator).  Notes  will also include  changes in 
conco mitant  medications  or dosages.  Included  in the progress  note will be all telephone  numbers or 
other  means of contact  that provide any significant  clinical information. Source  documents  and 
source  data will meet  the same fundamental  elements  of data quality  (e.g. attributable, legible,  and 
accurate)  
 
This study will use urine  Pregnancy  test and Urine  Toxicology  from  Nobel  Medical,  these  tests  have  
CLIA waiver  and will be conducted  prior to dosing.  Tests  will be conducted using  a urine  dipstick  or 
urine  cup. 
 
Noble  Medical  19525 Janacek  Court,  Suite  104 Brookfield,  WI 53045  877-836-5713 
info@noblemedical.com  John Hlavachek  john@noblemedical.com)  
  
1. NMCup -12-01-BT12PanelCup, CLIA Waived,  
AMP500/BAR300/BUP10/BZO300/COC150/MET500/MDMA500/MTD300/OPI300/OXY100/
TCA1000/THC50  
2.
 hCG  Women  Pregnancy  Strip,  25mIU/ml, Sample:  urine. 50 strips  each  box CLIA Waived  
 Note:  Urine  Drug  Screen  and Pregnancy  tests  are required within  24 hours of study intervention  
and results  available  prior to administration  of study product Azstarys  
 We will rely on their list of normal  and abnormal  values and will maintain all laboratory information  
in regulatory  binder. We will use an NYU  cardiologist  to read all EKGs  and respond  with  clinical  
judgement  to the investigator  regarding inclusion  or exclusion  of subjects  in accordance  with  Good  
Clinical Practices.  We will retain  all standard operating procedures  in the essential  documents  
folder and will also  circulate  among  the staff at start of  the project and  at each  amended  change. 
 
QC procedures  will be implemented  beginning  with  the data entry system.  Data  will be double  
entered  by two different study team  members.  Missing  data will be  logged  as a period. 
 Study  staff will follow  all written  SOPs,  the study principal  investigator  will verify that the clinical  
trial is conducted and data are generated,  documented  (recorded), and reported  in compliance with  
the protocol,  GCP,  and the applicable  regulatory  requirements  (e.g., Good  Laboratory Practices  
(GLP), G
ood  Manufacturing  Practices  (GMP)). 
 The investigational  site will provide direct access  to all trial related sites,  source  data/documents, 
and reports  for the purpose of monitoring and inspection  by local  and regulatory  authorities.  If 
required.  
 13. Ethics/Protection  of Human  Subjects  
 
13.1.  Ethical  Standard 
The investigator  will ensure  that this study is conducted in full conformity  with  Regulations for the 
Protection  of Human Subjects  of Research  codified in 45 CFR  Part 46, 21 CFR Part 50, 21 CFR Part 
56, and/or  the ICH E6. 
Study #: s22-01003   Page 53 of 64 
   
13.2.  Institutional Review Board 
The protocol,  informed  consent  form(s), recruitment materials,  and all participant materials  will be 
submitted  to the IRB for review  and approval. Approval  of both the protocol  and the consent  form  
must  be obtained  before  any participant  is enrolled.  Any a mendment  to the protocol  will require  
review  and approval by the IRB before the changes are implemented  to the study.  All changes to the 
consent  form  will be IRB approved; a determination  will be made regarding  whether  previously  
consented  participants  need to be re-consented.  
 
13.3.  Posting of Clinical Trial Consent  Form 
The informed  consent  form  will be posted  on the Federal website after the clinical trial is closed  to 
recruitment, and no later than 60 days  after the last study visit by any subject, as required by the 
protocol .  
 13.4.  Participant  and Data  Confidentiality  
Information  about  study  subjects  will be kept confidential  and managed  according  to the 
requirements  of the Health  Insurance  Portability and Accountability  Act of 1996 (HIPAA). Those 
regulations require  a signed  subject authorization informing  the subject of  the following:  
• W
hat  protected health information  (PHI) will be  collected  from  subjects  in this study.   
• Who  will have  access  to that information  and why.  
• Who  will use  or disclose  that information. 
• The rights  of a research  subject to  revoke their  authorization for use of their PHI.  
 
In the event  that a subject revokes  authorization to collect or use PHI,  the investigator,  by 
regulation, retains  the ability  to use all information  collected prior  to the revocation  of subject 
authorization. For subjects  that have  revoked  authorization to collect or use PHI,  attempts  should  
be made to obtain permission  to collect at least  vital  status  (i.e. that the subject  is alive)  at the end 
of their scheduled  study period. 
 Possible loss of confidentiality  related to urine  screens  and clinical data obtained  during  this study  
is recognized.  As a guard  against  the loss of confidentiality,  all information  will be stored in locked  
files,  which  can be accessed only by members  of the research  staff for this project.  
 In the event  that a subject revokes  authorization to collect or use PHI,  the investigator,  by 
regulation, retains  the ability  to use all information  collected prior  to the revocation  of subject 
authorization. Fo
 r subjects  that have  revoked  authorization to collect or use PHI,  attempts  should  
be made to obtain permission  to collect at least  vital  status  (i.e. that the subject  is alive)  at the end 
of their scheduled  study period. 
 Participant confidentiality  is strictly  held in trust by the participating  investigators,  their staff, and 
Corium  LLC(s) and their agents. This confidentiality  is extended  to cover  testing of biological 
samples  in addition to the clinical  information  relating  to participants.  Therefore,  the study protocol,  
documentation, data, and all other  information  generated  will be held in strict confidence.  No 
information  concerning  the study or the data will be released  to any unauthorized third party  
without  prior w ritten  approval of Corium  LLC.  
 The study monitor,  other  authorized  representatives  of the Corium  LLC, representatives  of the IRB 
or pharmaceutical  company  supplying  study product may inspect  all documents  and records  
Study #: s22-01003   Page 54 of 64 
  required to be maintained  by the investigator,  including  but not limited  to, medical records  (office, 
clinic,  or hospital)  and pharmacy  records  for the participants  in this study.  The clinical study site 
will permit  access  to such  records.  
 
The study participant’ s contact  information  will be securely stored at each  clinical site for internal  
use during  the study.  At the end of the study,  all records  will continue  to be kept in a secure  location  
for as long a period  as dictated by local  IRB and Institutional  regulations.  
 
Study  participant research  data, which  is for purposes of statistical  analysis and scientific  reporting,  
will be transmitted  to and stored at NYU Langone  Medical Center.  This will not include  the 
participant’ s contact or identifying  information. Rather,  individual  participants  and their research  
data will be identified  by a unique  study identification  number. The study data entry  and study  
management  systems  used  by clinical sites and by NYU Langone  Medical Center research  staff will 
be secured and password  protected.  At the end of the study,  all study databases will be de-identified 
and archived at the NYU Langone  Medical Center.  
 We
 will not store  any human samples.  We will store  the study data.  The source  documents  will be 
all the clinical  findings and observations collected either  on the actual  scale or on the specific source  
documents  for each  study visit.  This will include  all urine  pregnancy  and drug toxicology  laboratory  
and EKG results.  The results  of the documents  will be entered  into REDCap  and rechecked  for 
accuracy.  The REDCap  form  will have  a check  off at the bottom  of the page  indicating  completion  of 
entry  into REDCap  
 REDCap  is a secure  web application  used  to collect virtually  any type of data (including  21 CFR Part 
11, FISMA,  and HIPAA -compliant  environments). REDCap  supports online  or offline data capture  
for research  studies  and operations.  Deidentified  data from  REDCap  may be exported  into Excel  
spreadsheets  for analysis.  
 Subjects  are called  three  times  a day from  an NYU mobile device.  TASS/AMES information  will be 
entered  directly  into REDCap.   
 Dr. Adler will handle  statistical analysis of this study.  
  14. Data Handling  and Record Keeping 
14.1.  Data  Collection  and Management Responsibilities  
In th
is  study,  data will be collected,  stored (digital,  hard  copy,  etc.) and maintained  in a secure  
manner  (encryption,  password  protection,  etc.).  Only minimal information  will be collected from  the 
prescreens.  Prescreens  will be destroyed  after all necessary  information  is collected.  The prescreens  
of those  who have  passed  to screening  will be added to a source  chart and  stored in a locked  cabinet  
in a locked  room  until  eligibility  is determined.  Once  eligible,  the subject is baselined and all source  
documents  are stored in the same manner  in a locked  room  in a locked  cabinet. Data  will be entered  
into the secure  data capture  system REDCap.  Unidentified  data will also be stored  in our shared  
drive  for writing  purposes. 
 
The documentation  into the source  documents  for research  visits  should  occur in real time and no 
later than 4 business  days  from  the date of the visit.  in the case of vacation  or holiday. If the 
documentation is later than four business days,  this should be considered  a late entry  with  an 
Study #: s22-01003   Page 55 of 64 
  explanation. Documentation  of the data should  occur within  7 business days  of the visit.  If not 
entered  within  that time  period, we will document  in the source  documents  the reason  for the delay.  
 
Source Documents  
Source  data is all information, original  records  of clinical findings,  observations, or other  activities  
in a clinical trial necessary  for the reconstruction and evaluation of the trial.  Source  data are 
contained  in source  documents.  Examples  of these  original documents,  and data records  include:  
hospital  records,  clinical and office charts,  laboratory notes,  memoranda, subjects'  diaries  or 
evaluation checklists,  pharmacy  dispensing  records, recorded  data from  automated instruments,  
copies  or transcriptions  certified after verification  as being  accurate  and complete,  microfiches,  
photographic negatives,  microfilm or magnetic  media,  x-rays,  subject  files,  and records  kept at the 
pharmacy, at the laboratories,  and at medico -technical  departments  involved  in the clinical trial.  
 Case  Report Forms  
The study case report form  (CRF)  is the primary  data collection  instrument  for the study.  All data 
requested  on the CRF  must  be recorded.  All missing  data must  be explained. If a space  on the CRF  
is l
eft blank  because  the procedure  was not done or the question  was not asked,  write  "N/D".  If the 
item  is not applicable  to the individual  case,  write  "N/A".  All entries  should  be printed  legibly  in 
black  ink. If any entry  error has been  made, to correct such  an error,  draw  a single  straight line 
through  the incorrect entry and enter  the correct data above  it. All such  changes must  be initialed  
and dated. DO NOT  ERASE OR WHITE  OUT  ERRORS.  For clarification  of illegible or uncertain  
entries,  print the  clarification above  the item,  then  initial and date it. 
 Data  collection  is the responsibility  of the clinical  trial staff at the site under  the supervision  of the 
site PI. The investigator  is responsible  for ensuring  the accuracy, completeness,  legibility,  and 
timeliness  of the data reported.  
 
All source  documents  should  be completed  in a neat, legible  manner  to ensure  accurate  
interpretation  of data. Black  ink is required to ensure  clarity  of reproduced  copies.  When  making  
changes or corrections, cross  out the original  entry  with  a single  line, and initial and date the change. 
DO NOT  ERASE,  OVERWRITE,  OR USE CORRECTION  FLUID OR TAPE ON THE  ORIGINAL.  
 C
opies  of the electronic  CRF  (eCRF) will be provided  for use as source  documents  and maintained  
for recording  data for each  participant enrolled  in the study.  Data  reported in the eCRF  derived  from  
source  documents  should  be consistent with  the source  documents  or the discrepancies  should  be 
explained  and captured in a progress  note and maintained in the participant’ s official electronic  
study record.  
 
Clinical data (including  AEs,  concomitant medications,  and expected  adverse  reactions  data) and 
clinical laboratory  data will be entered into REDCap,  a 21 CFR Part 11-compliant  data capture  
system.  The data system includes password  protection  and internal  quality  checks,  such  as 
automatic  range  checks,  to identify data that appear inconsistent,  incomplete,  or inaccurate.  Clinical 
data will be  entered  directly  from  the source  documents.  
 14.2.  Study  Records Retention 
 Records Retention  
It is the investigators  responsibility  to retain  study records.  Study  documents  will be retained for 
the longer  of 3 years  after close -out,  5 years  after final  reporting/publication, or 2 years  after the last 
Study #: s22-01003   Page 56 of 64 
  approval of a marketing  application  is approved for the drug  for the indication  for which  it is being  
investigated  or 2 years  after the investigation  is discontinued  and FDA  is notified  if no application  
is to be filed or if the application  has not been  approved  for such  indication.  No records  will be 
destroyed  without  the written  consent  of Corium  LLC, if applicable. It is the responsibility  of Corium  
LLC to inform  the investigator  when  these  documents  no longer  need  to be retained.  
 
14.3.  Protocol Deviations  
Protocol  deviations  or violations  (includes intentional  and accidental/unintentional  deviations 
from  the IRB approved protocol) for any of the following  situations:  
• One or more  participants  were  placed at  increased risk of harm  
• The event  has the potential  to occur again 
• The deviation  was necessary to protect a subject from  immediate harm  
 
In the event  of a significant  deviation  from  the protocol  due to an emergency,  accident,  or mistake  
(e.g., violation  of informed  consent  process,  IMP dispensing  or subject dosing  error,  treatment 
assignment  error,  subject enrolled  in violation  of eligibility  criteria  or concomitant medication  
criteria),  th e investigator  or designee  will contact Corium  LLC or designee at the earliest  possible  
time by telephone.  The investigator,  medical monitor  and Corium  LLC will come as quickly  as 
possible  to a joint decision  regarding  the subject's  continuation  in the trial.  This decision  will be 
documented  by the investigator  and Corium  LLC,  and reviewed  with  the Data  Safety Monitor  
 A protocol  deviation  is any noncompliance  with  the clinical trial protocol,  GCP,  or Manual  of 
Procedures  (MOP) requirements.  The noncompliance  may be either  on the part of the participant,  
the investigator,  or the study site staff. As a result  of deviations,  corrective  actions  are to be 
developed  by the site and implemented  promptly.  
 These practices  are consistent  with  ICH E6: 
• 4.5 Compliance with  Protocol,  sections  4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality  Assurance  and Quality  Control,  section  5.1.1 
• 5.20 Noncompliance,  sections  5.20.1, and 5.20.2. 
 
It is the responsibility  of the site PI/study staff to use continuous vigilance to identify and report  
deviations within  7 working  days  of identification  of the protocol  deviation, or within  7 working  days  
of the scheduled  protocol -required activity.  
 
Al
l protocol  deviations must  be addressed  in study  source  documents,  reported to Corium  LLC and 
IRB   
Protocol  deviations must  be reported  to the local  IRB per their  guidelines.  The site PI/study staff is 
responsible  for knowing  and adhering  to their IRB requirements.  Further details  about  the handling  
of protocol  deviations will be  included  in the MOP.  
 
14.4.  Publication and Data  Sharing  Policy  
The investigator  at NYU will have  the primary  responsibility  for publishing  the study results.  The 
data will be  analyzed and discussed  prior to submission  of the study results  for publication. 
 
Study #: s22-01003   Page 57 of 64 
  Neither the complete  nor any part of the results  of the study  carried out under  this protocol,  nor any 
of the information  provided by Corium  LLC for the purposes of performing  the study,  will be 
published or passed  on to any third  party  without  the consent  of the study  investigator  of this study.  
 
This study will comply  with  the NIH Public  Access  Policy,  which  ensures that the public  has access  
to the published results  of NIH funded research.  It requires scientists  to submit  final  peer-reviewed  
journal  manuscripts  that arise from  NIH funds to the digital  archive  PubMed Central  upon 
acceptance  for publication.  
 The International  Committee  of Medical  Journal  Editors  (ICMJE)  member  journals have  adopted a 
clinical trials  registration  policy  as a condition  for publication. The ICMJE  defines a clinical trial as 
any research  project  that prospectively  assigns  human subjects  to intervention  or concurrent  
comparison  or control  groups  to study the cause -and-effect relationship  between  a medical 
intervention  and a health  outcome.  Medical interventions  include  drugs,  surgical  procedures, 
device s, behavioral  treatments,  process -of-care  changes, and the like. Health  outcomes  include  any 
biomedical  or he
 alth-related  measures obtained  in patients  or participants,  including  
pharmacokinetic  measures  and adverse  events.  The ICMJE  policy,  and the Sectio n 801 of the Food  
and Drug Administration  Amendments  Act of 2007, requires  that all clinical trials  be registered in 
a public  trials  registry  such  as ClinicalTrials.gov,  which  is Corium  LLCed  by the National  Library  
of Medicine.  Other biomedical  journals a re considering  adopting similar  policies.  For interventional  
clinical trials  performed  under  NIH IC grants and cooperative  agreements,  it is the grantee ’s 
responsibility  to register the trial in an acceptable  registry,  so the research  results  may be 
considered  for publication in ICMJE member  journals. The ICMJE does not review  specific  studies  
to determine  whether  registration  is necessary;  instead, the committee recommends  that 
researchers  who have  questions about  the need  to register err on the side of registration  or consult  
the editorial  office of the journal  in which  they wish  to publish.  
 FDAAA  mandates that a "responsible  party" (i.e., tCorium  LLC or designated  principal  investigator)  
register and  report results  of certain  "applicable  clinical trials":  
• Trials  of Drugs  and Biologics:  Controlled,  clinical investigations,  other  than Phase  I 
investigations  of a p
 roduct subject to FDA  regulation;  
• Trials  of Devices:  Controlled  trials  with  health outcomes  of a product subject  to FDA  
regulation  (other  than small feasibility  studies)  and pediatric post-market  surveillance  studies.  
• NIH grantees  must  take specific  steps  to ensure  compliance  with  NIH implementation  of 
FDAAA.  
 15. Study Finances  
 
15.1.  Funding  Source 
Corium  LLC will provide the study with  funding  to purchase  Azstarys  in this study.  
 
Charles  Oh, MD 
Chief  Medical Officer at Corium,  LLC 
coh@coriumintl.com  
11 Farnsworth  Street 4th Floor  
Boston,  MA 02210 
 
Study #: s22-01003   Page 58 of 64 
   
15.2.  Costs to the Participant 
Participants  will not incur  any costs  as a result  of participating  in the study.  All research  activities  
are paid by the Azstarys  study.   
 
15.3.  Participant  Reimbursements or Payments 
Participants  will receive  payments for the time,  effort,  and inconvenience  of study  participation.  
ClinCards  will make  payments for completed  visits  as indicated  below.  Participants  will be given  
reimbursement  after each  completed  visit on their ClinCard.  Their selection  will be documented  on 
the consent  form,  the subject binder, and the administrative binder. Pharmacy  dispensation  cost to 
Turtle  Bay Pharmacy  will be  added at  each  visit for three  visits  to ClinCards.   
  
 
 16. Conflict  of Interest Policy 
All study  members  will complete  the NYU financial  disclosure forms.  Dr. Adler,  who may have  
conflict of interest with  studies  (patent ownership,  royalties,  or financial  gain greater than the 
minimum allowable  by their institution,  etc.),  will have  any conflict reviewed  by a properly 
constituted Conflict of Interest Committee.  A Committee  sanctioned conflict management  plan that 
has been  reviewed  and approved by Corium  LLC prior to participation  in this study.  All NYULMC  
investigators  w
 ill follow  the applica ble University  conflict of interest policies.  
 The independence of this study  from  any actual  or perceived  influence,  such  as by the 
pharmaceutical  industry,  is critical.  Therefore,  any actual  conflict of interest of persons  who have  a 
role in the design,  conduct, analysis,  publication, or any aspect of this trial will be disclosed  and 
managed. Furthermore,  persons  who have  a perceived  conflict of interest  will be required to have  
such  conflicts  managed  in a way that is appropriate to their  participation  in the trial.  The study  Visit  1 Visit  2 Visit  3 Visit  4 Visit  5 Visit  6 Visit  7 ClinCard  
Patient  
Reimbursem
ent 
Week  -3-0 
Screening/B
aseline  Week  -3-0 
Screening/B
aseline  Week1  
 
Two-week  
Observation 
Stabilization 
period) - 
telephone 
check  Week  2 
 
Initiation  
Dose  Week3  
 
Flexible-
Dose] Week  4 
 
Dose 
locked] Week  5 
 
EOS Week  6 
 
GCP  
Telephon
e check  After  
completed 
visits  
  Observation  
stabilization  Pharmacy  
Dispensatio
n cost 
120.00  Pharmacy  
Dispensatio
n cost 
120.00  Pharmacy  
Dispensatio
n cost 
120.00  No 
dispensation  No 
dispensati
on 360.00  for (3) 
pharmacy  
dispensations  
 This visit is 
not 
completed 
and done  
remote (no 
compensati
on) 40.0 
(completion 
of both 
parts  of 
visits) 10.00  40.00  40.00  40.00  40.00  10.00  Total:  220.00  
Study #: s22-01003   Page 59 of 64 
  leadership  has established policies and procedures  for all study group  members  to disclose all 
conflicts  of interest and will establish  a mechanism for the management  of all reported  dualities  of 
interest.   
 
Any investigator  who has a conflict of interest with  this study (patent  ownership, royalties,  or 
financial  gain greater than the minimum allowable  by their institution,  etc.) must  have  the conflict  
reviewed  by the NYU Langone  Conflict of Interest  Management Unit (CIMU)  with  a Committee -
sanctioned conflict management  plan that has been  reviewed  and approved by Corium  LLC prior to 
participation  in this study.  All NYULMC investigators  will follow  the applicable  conflict of interest  
policies.  
 
17. References 
1. Adler,  L. A., Lynch, L. R., Shaw,  D. M., Wallace, S. P., O'Donnell,  K. E., Ciranni,  M. A., 
Briggie,  A. M., & Faraone, S. V. (2017). Effectiveness  and Duration  of Effect of Open -Label  
Lisdexamfetamine Dimesylate in Adults  With  ADHD.  Journal  of attention  disorders,  21(2),  
149– 157. https://doi.org/10.1177/1087054713485421 
2. Adler L.A., Spencer T.J., Milton  D.R., Moore R.J., Michelson  D. (2005). Long-term,  open -label  
study of the safety and efficacy  of atomoxetine in adults with  attention -deficit/hyperactivity  
disorder:  an i nterim  analysis.  J Clin Psychiatry.  2005 Mar;  66(3):294-9. PMID:  15766294 
3. Adler,  L. A., Spencer,  T., Faraone, S. V., Kessler,  R. C., Howes,  M. J., Biederman,  J., & Secnik,  
K. (2006). Validity  of pilot  Adult ADHD Self-Report Scale  (ASRS)  to rate adult  ADHD  
symptoms.  Annals of Clinical Psychiatry, 18, 145-148. doi:10.1080/10401230600801077 
4. Adler L. A., Alperin  S., Leon  T., Faraone  S. (2014). Clinical effects  of lisdexamfetamine and 
mixed  amphetamine  salts  immediate release  in adult  ADHD:  results  of a crossover  design  
clinical trial.  Postgrad Med. 126(5):17-24. doi: 10.3810/pgm.2014.09.2796. 
5. Adler L.A.,  Clemow  D.B., Williams  D.W., Durell  T.M. (2014). Atomoxetine  effects  on 
executive  function  as measured  by the BRIEF --a in young  adults with  ADHD:  a randomized, 
double -blind,  placebo -controlled study.  PLoS One.  9(8):e104175. doi: 
10.1371/journal.pone.0104175. eCollection  2014 
6. Adler,  L. A., & Gorny,  S. W. (2015). Pilot  study of droxi -dopa with  carbidopa  in adults with  
ADHD.  Journal  of Attention  Disorders.  Advance  online  publication. 
doi:10.1177/1087054715580393 
7. Adler,  L. A., Orman, C., Starr,  H. L., Silber,  S., Palumbo,  J., Cooper,  K., & Harrison,  D. D. 
(2011). Long- term  safety of OROS methylphenidate  in adults  with  attention -
deficit/hyperactivity disorder:  An open -label, dose-titration,  1-year  study.  Journal  of Clinical  
Psychopharmacology, 31, 108-114. doi:10.1097/JCP.0b013e318203ea0a  
8. Adler,  L. A., Shaw, D. M., & Alperin,  S. (2015). ADHD diagnostic  and symptom assessment  
scales for adults. In L. A. Adler (Ed.), Attention -deficit hyperactivity  disorder in adults and 
children  (pp. 224-232). Cambridge,  UK: Cambridge  University  Press.  
9. Adler LA,  Faraone  SV, Spencer TJ, Berglund  P, Alperin  S, Kessler  RC (2017). The structure  
of adult  ADHD.  Int J Methods  Psychiatr Res. doi: 10.1002/mpr.1555. Epub  2017 Feb 17. 
American  Psychiatric  Association.  (2013). Diagnostic  and statistical  manual  of mental 
disorders  (5th ed.). Arlington,  VA: American  Psychiatric Publishing.  
10. Adler L A,  Shaw  DM, Spencer  TJ, Newcorn  JH, Sitt DJ, Morrill M, Davidow JV, Glatt  SJ, 
Faraone  SV. Reliability  and validity  of the Time-Sensitive  ADHD Symptom  Scale  in adults.  
Compr Psychiatry.  2011 Nov-Dec;52(6):769-73. doi: 10.1016/j.comppsych.2010.12.002. Epub  
2011 Feb 8. PMID:  21306705.  
 
Study #: s22-01003   Page 60 of 64 
  11. Barkley,  R. A., & Murphy, K. R. (2010). Impairment  in occupational  functioning  and adult  
ADHD:  The predictive  utility  of Executive  Function  (EF) ratings versus  EF tests.  Archives  of 
Clinical Neuropsychology,  25, 157-173. 
12. Bron,  T. I., Bijlenga,  D. Boonstra,A.  M., Breuk,  M.,Pardoen, W. F.,Beekman, A. T.,& Kooij,  
J. J. (2014). OROS-Methylphenidate  Efficacy on Specific Executive  Functioning  Deficits  in 
Adults  with  ADHD:  A 
13. Randomized, Placebo -Controlled  CrossoverStudy.  European  Neuropsychopharmacology: The 
Journal  of the European  College  of Neuropsychopharmacology, 24(4), 519– 28. 
14. Busner  J, Targum  SD. The clinical global  impressions  scale:  applying a research  tool in 
clinical practice. Psychiatry.  2007;4(7):28-37. Canadian ADHD Resource  Alliance.  CADDRA.  
(n.d.). Retrieved  May 19, 2022,  from  https://www.caddra.ca/https://www.caddra.c a/wp -
content/uploads/CADDRA-Guidelines-4th -Edition_ -Feb2018.pdf  
15. Goodman, D. W., Starr,  H. L., Ma, Y. W., Rostain,  A. L., Ascher,  S., & Armstrong,  R. B. (2017). 
Randomized, 6-week,  placebo  controlled study of treatment  for adult  attention -
deficit/hyperactivity disorder:  Individualized  Dosing  of Osmotic -Release  Oral  System (OROS)  
methylphenidate  with  a goal of symptom remission.  Journal  of Clinical  Psychiatry,  78, 105-
114. doi:10.4088/JCP.15m10348 
16. F araone  SV, Biederman  J, Spencer T, Michelson  D, Adler L, Reimherr F, Seidman  L. (2005).  
Atomoxetine  and stroop task performance  in adult attention -deficit/hyperactivity  disorder.  J 
Child  Adolesc  Psychopharmacol. 2005 Aug;  15(4):664-70. PMID:  1619079 
17. Kessler,  R. C., Adler,  L., Barkley,  R., Biederman,  J., Conners,  C. K., Demler,  O., Zaslavsky, 
A. M. (2006). The prevalence  and correlates  of adult  ADHD in the United  States:  Results  
from  the National  Comorbidity Survey Replication.  American  Journal  of Psyc hiatry,  163, 
716-723. 
18. Kollins,  S. H., Braeckman, R., Guenther,  S., Barrett,  A. C., Mickle,  T. C., Oh, C., Marraffino,  
A., Cutler,  A. J., & Brams,  M. N. (2021). A Randomized, Controlled  Laboratory  Classroom  
Study  of Serdexmethylphenidate  and d-Methylphenidate  Capsules in Childre n with  
Attention -Deficit/Hyperactivity  Disorder.  Journal  of child  and adolescent  
psychopharmacology, 31(9), 597– 609. https://doi.org/10.1089/cap.2021.0077 
19. Manor, I., Ben-Hayun, R., Aharon -Peretz,  J., Salomy,  D., Weizman, A., Daniely,  Y., Megiddo, 
D., Newcorn,  J., Biederman, J.,and  Adler,  L. A. (2012). A Randomized, Double -blind,  Placebo -
controlled,  Multicenter Study  Evaluating  the Efficacy,  Safety,  and Toler ability  of Extended -
release  Metadoxine  in Adults  with  Attention -Deficit/Hyperactivity  Disorder.  The Journal  of 
Clinical P sychiatry, 73(12), 1517– 1523. 
20. National  Center for Biotechnology  Information  (2022). PubChem  Compound  Summary  for 
CID 134823895, Serdexmethylphenidate.  Retrieved  June  7, 2022 from  
https://pubchem.ncbi.nlm.nih.gov/compound/Serdexmethylphenidate. 
21. Silverstein  MJ, Faraone  SV, Alperin  S, Leon  TL, Biederman  J, Spencer  TJ, Adler LA. (2018).  
Validation  of the Expanded Versions  of the Adult ADHD  Self-Report Scale  v1.1 Symptom  
Checklist  and the Adult ADHD  Investigator Symptom  Rating J Atten  Disord.  2018 Feb 
1:1087054718756198. doi: 10.1177/1087054718756198. [Epub ahead  of print]  
22. Spencer TJ, Adler LA, Weisler  RH, Youcha SH (2008)  Triple-bead mixed  amphetamine  salts 
(SPD465), a novel,  enhanced  extended -release amphetamine  formulation  for the treatment 
of adults with  ADHD:  a randomized, double -blind, multicenter,  placebo -controlled s tudy.  J 
Clin Psychiatry. 2008 Sep;69(9):1437-48. Epub  2008 Sep 9. 
23. Spencer,  T. J., Adler,  L. A., Qiao,  M., Saylor,  K. E., Brown,  T. E., Holdnack, J. A.,. . . Kelsey,  
D. K. (2010). Validation  of the Adult Investigator  Symptom  Rating Scale  (AISRS).  Journal  of 
Attention  Disorders,  14, 57-68. Spencer,  T. J., Biederman,  J., Wilens,  T., Faraone, S., Prince,  
J., Gerard,  K., . . . Bearman, S. 
Study #: s22-01003   Page 61 of 64 
   
Study #: s22-01003   Page 62 of 64 
   
 
18. Schedule  of Events  
Study  team  
procedures  Week  -3-0 
Visit  1 
 
Screening  / 
Baseline  Week  -3-0 
Visit  1 
 
Screening  / 
Baseline  Week  1 Visit  2 
Two -week  
Observation  
Stabilization  
period - 
telephone  check  Week  2 Visit  3 
Initiation  
Dose  Week  3 Visit  4 
Flexible -Dose  Week  4 Visit  5 
Dose  locked  Week  5 Visit  6 
EOS  Dose  hold  Week  6 Visit  7 
GCP  Telephone 
check  
 Visit  1 Visit  1 Visit  2(TC)  Visit  3 Visit  4 Visit  5 Visit  6 Visit  7 (TC) 
OPEN -LABEL  
AZSTARYS  
Dispensed  @ visit 
Dispensation  
dose starts  the 
morning  after  
visit to clinic.  The 
next morning  
subject  will take 
first dose Screening   Screening   Zero 39.2 mg serd-
mph/7.8  mg d-
mph up to 52.3 mg 
serd-mph/10.4 
mg d-mph up to 52.3 mg 
serd-mph/10.4 
mg d-mph/hold  
dose EOS  no 
dispensation  0 
Dose  patient  is 
on that day. 
 
Subject  on this 
dose for 7 days  Screening   Screening   Zero  0 
 39.2 mg serd-
mph/7.8  mg d-
mph up to 52.3 mg 
serd-mph/10.4 
mg d-mph up to 52.3 mg 
serd-mph/10.4 
mg d-mph 0 
Consent  X        
Demographics  X        
MINI  X        
ACDS  v1.2 X        
AISRS  X   X X X X  
CGI S X   X X X X  
Psychiatric  
History  X        
Study #: s22-01003   Page 63 of 64 
  CSSRS  X  X X X X X  
Medical  
History/Prior  
Meds  X        
Physical  Exam  X        
Height  X        
Weight  X   X X X X  
Vitals  signs  X   X X    
Study drug  / 
dispensation     X  X X   
Subject  IP 
compliance  check     X X X X  
Clinician  RX / 
Dose  Adjustment     X X X X  
Expanded  ASRS  X X 
(if not done  
at first part 
of screening)   X X X X  
Brief  A X   X X X X  
Adverse  Events  X X X X X X X 
Con Meds   X X X X X X X 
TASS  (3x on 
assessment  visit 
day)  X(instruction
)  X X X X  
Study #: s22-01003   Page 64 of 64 
  Smoothness  of 
Effect  Scale  
(AMSES) (3x day 
on assessment  
visit day)  X(instruction
)  X X X X  
Electrocardiogra
m X        
Urine  Pregnancy  
dipstick  Ask 
LMP/Birth  
control    X     
Urine  Toxicology 
cup  X  X     
 
 